BREATHER SYSTEM FOR AN INTERNAL COMBUSTION ENGINE

A breather system of an internal combustion engine suitable for use on a motorcycle. A gearbox has a housing () forming a gearbox cavity () in which a gear selector drum () is provided. The selector drum () has an elongate hollow structure and has an outlet opening () at or adjacent a first end. The selector drum () is provided with at least one inlet () hole provided in a sidewall thereof, within the gearbox cavity (), such that a breather flow path extends from the inlet () to the outlet opening (). 1. A breather system for an internal combustion engine , the breather system comprising:a gearbox having a housing forming a gearbox cavity, said gearbox cavity having a selector drum therein; whereinsaid selector drum has an elongate hollow structure having an outlet opening at or adjacent a first end; andsaid selector drum is provided with at least one inlet hole provided in a sidewall thereof, within the gearbox cavity, such that a breather flow path extends from said at least one inlet to said outlet opening.2. The breather system according to wherein the selector drum is provided with a plurality of inlet holes therein.3. The breather system according to wherein said selector drum has one or more surface features thereon configured to transmit movement of said selector drum in a rotational or axial direction to at least one gear.4. The breather system according to further comprising a plurality of shifter plates slideably mounted on at least one guide rod and wherein said surface features of said selector drum are configured to move said at least one shifter plates on said guide rod.5. The breather system according to wherein said surface features comprise a plurality of cam tracks which extend radially from said selector drum6. The breather system according to wherein each of said cam tracks is configured to engage with a different shifter plate within said gearbox.7. The breather system of wherein said at least one inlet hole is provided between said cam tracks. ...

Rotatable stage

COLLAPSIBLE CARGO ORGANIZER

Described is a cargo apparatus (10) including a base (16) having at least one end (30) and at least one side(28), with the at least one end having at least one laterally inside post (20) extending therefrom, and with the at least one side having at least one laterally outside post (18) extending therefrom. At least one end bracket (24) and at least one side bracket (22) are pivotably and translatably mounted to the base, wherein the brackets each have at least one support leg (38, 44) with a mounting end (42, 48). The mounting end pivotably mounts to its respective post on the base between open and closed positions and also translatably mounts to its respective post between an unlocked position distal the post and a locked position proximal the post, whereby the apparatus is collapsible to a closed portable position, and is foldable to a sturdy, open position.

Edge coating for honeycomb used in panels with composite face sheets

Core-skin bonding is improved between honeycomb and composite face sheets by applying a nylon-based (polyamide) adhesive to the edge of the honeycomb prior to bonding. Edge coating of honeycomb with polyamide adhesives is useful in further increasing the bond strength between honeycomb and prepreg face sheets, especially when the matrix resin of the prepreg is designed to adhere the prepreg to the honeycomb.

Rotatable stage

A rotatable stage comprising: a stator 16; a heat exchanger 32, in thermal connection with the stator; a rotor 18; and, a bearing 20, located between the stator and the rotor. The material of the bearing has a thermal conductivity of greater than about 170Wm-1K-1, to provide a thermal connection between the stator and rotor. The stage is for an analytical apparatus. The bearing may provide 12 points of contact with the stator and rotor, and may be formed from at least one of copper, phosphor, bronze and CuBe2. The bearing is preferably a canted coiled spring. The heat exchanger may comprise a gas tube 32 or thermally conductive braid, preferably made from copper. Cooling the heat exchanger of the stator may cool the rotor via the bearing. The stator may comprise a temperature sensor. An electron microscope comprising a vacuum chamber and the rotatable stage is also disclosed.

METHODS TO INHIBIT GROWTH OF PROSTATE CANCER CELLS

A novel gene (designated 101P3A11 or PHOR-1) and its encoded protein, and variants thereof, are described wherein 101P3A11 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 101P3A11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 101P3A11 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 101P3A11 can be used in active or passive immunization.

Nucleic acid and corresponding protein entitled 121P2A3 useful in treatment and detection of cancer

A novel gene (designated 121P2A3) and its encoded protein, and variants thereof, are described wherein 121P2A3 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 121P2A3 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 121P2A3 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 121P2A3 can be used in active or passive immunization.

Aircraft floor panels using edge coated honeycomb

Aircraft floor panels where core-skin bonding is improved between honeycomb and composite face sheets (skins) by applying a nylon-based (polyamide) adhesive to the edge of the honeycomb prior to bonding. Edge coating of the honeycomb allows one to reduce panel weight without reducing the performance parameters that are required for different types of aircraft floor panels.

Nucleic acid and corresponding protein entitled 158P3D2 useful in treatment and detection of cancer

A novel gene (designated 158P3D2) and its encoded protein, and variants thereof, are described wherein 158P3D2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 158P3D2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 158P3D2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 158P3D2 can be used in active or passive immunization.

Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer

A novel gene 0161P2F10B (also designated 161P2F10B) and its encoded protein, and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.

Nucleic acid and corresponding protein entitled 184P1E2 useful in treatment and detection of cancer

A novel gene (designated 184P1E2) and its encoded protein, and variants thereof, are described wherein 184P1E2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 184P1E2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 184P1E2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 184P1E2 can be used in active or passive immunization.

TRANSMISSION DEVICE WITH POWER SPLITTING

A transmission with power branching, and the transmission, in a first drive range, transmits torque from the ring gear to a fixed wheel. In one branch, power is transmitted from a first to a second hydraulic unit which respectively operate as a pump and a motor. At one of the hydrostatic shafts, the mechanical and hydrostatic power are summed and transmitted to the drive output. In a second drive range, power coming from the planetary carrier is partially branched off to the ring gear and transmitted, via the gear wheels of the hydrostatic shaft, to the second hydraulic unit. From the second hydraulic unit, hydraulic power passes to the first hydraulic unit. In the process, the first hydraulic unit operates as a motor and the second hydraulic unit as a pump. From the second sun gear, power is transmitted to the double planetary gear and summed. 114-. (canceled)1511. A transmission device () with power branching , the transmission device () comprising:{'b': 3', '5, 'a first power branch () and a second power branch (),'}{'b': 9', '3', '5, 'with a transmission arrangement () in a form of a planetary gear system for summing parts of applied torque that are transmittable by way of the first and the second power branches (, ),'}{'b': 4', '10', '11', '10', '29', '11', '28', '1', '3', '1', '3', '1', '3', '14', '15', '16, 'a hydrostatic device () having a first hydraulic unit () and a second hydraulic unit (), the first hydraulic unit () being connected to a second hydrostatic shaft () and the second hydraulic unit () being connected to a first hydrostatic shaft () such that, in each case, first, second and third driving ranges, for forward and reverse driving, are provided which can be shifted, respectively, between by at least one shifting element (K to K) that has to be disengaged and at least one shifting element (K to K) that has to be engaged, and each of the shifting elements (K to K) being arranged on a separate countershaft (, ),'}{'b': 21', '22', '23', '25', '24', ...

Specimen tip and tip holder assembly

A specimen tip holder assembly for mounting a specimen tip in a transmission electron microscope (TEM) is described. The specimen tip holder assembly comprises a tip holder for supporting a specimen tip. The tip holder is coupled to an elongate support for movement in a direction substantially perpendicular to the axis of the support. An actuator is mounted to the support for causing motion of the tip holder relative to the support.

TRANSMISSION DEVICE HAVING POWER SPLITTING

A transmission device having power splitting. In the first driving range, the mechanical power branch transmits torque from the ring gear to the additional fixed gear by the fixed gear. In this case, power branches from the ring gear. The hydrostatic power branch branches from the second sun gear. The hydrostatic branch transmits power from the first to the second hydraulic unit. The first and second hydraulic units act respectively as a pump and a motor. On one of the hydrostatic shafts, the mechanical and hydrostatic powers are added and transmitted to the output. In the second driving range, power from the planet carrier partially branches to the ring gear and passes to the hydrostatic shaft for the second hydraulic unit. An auxiliary shaft can be coupled by a gear to a fixed gear operatively connected to a shaft of the power splitting device.

System and method for clock independent pulse width modulation

A method of clocking a video processing circuit by stalling a reference clock signal based on a stall signal from a clock-independent pulse width modulator to produce a video clock signal for use by an image data processing circuit.

Aircraft floor panels using edge coated honeycomb

Aircraft floor panels where core-skin bonding is improved between honeycomb and composite face sheets (skins) by applying a nylon-based (polyamide) adhesive to the edge of the honeycomb prior to bonding. Edge coating of the honeycomb allows one to reduce panel weight without reducing the performance parameters that are required for different types of aircraft floor panels.

Nucleic acid and corresponding protein entitled 121P2A3 useful in treatment and detection of cancer

A novel gene (designated 121P2A3) and its encoded protein, and variants thereof, are described wherein 121P2A3 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 121P2A3 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 121P2A3 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 121P2A3 can be used in active or passive immunization.

Rotatable stage

A rotatable stage for an analytical apparatus. The rotatable stage has a stator, a heat exchanger in thermal connection with the stator, a rotor and a bearing located between the stator and the rotor. The bearing provides a thermal connection between the stator and rotor.

TOILET TANK PLUMBING FIXTURE ASSEMBLY

A plumbing fixture assembly for a toilet tank comprising an upper portion that connects with a valve, a lower portion adapted for engagement with the upper portion, and an attachment pipe that that connects at a first end with lower portion and at a distal end with a supply line.

Nucleic acids and corresponding proteins entitled 101P3A11 or PHOR-1 useful in treatment and detection of cancer

A novel gene (designated 101P3A11 or PHOR-1) and its encoded protein, and variants thereof, are described wherein 101P3A11 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 101P3A11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 101P3A11 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 101P3A11 can be used in active or passive immunization.

Board game

A board game for challenging players to move all of their game pieces from the start space to the finishing space. The board game includes a game board having a first path and a second path. The first path encompasses the second path. The first and second paths are connected by a plurality of connector paths. The first path, the second path and the plurality of connector paths are divided into path spaces. A plurality of starting spaces on the game board are located generally adjacent the first path. A plurality of ending paths are connected to the first path. A plurality of sets of game pieces. A plurality of cards for indicating movement of game pieces about the game board. Wherein cards are drawn to determine movement of the game pieces about the first path. The game is won by moving the set of game pieces to the end of the ending path.

Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer

A novel gene (designated 213P1F11) and its encoded protein, and variants thereof, are described wherein 213P1F11 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 213P1F11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 213P1F11 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 213P1F11 can be used in active or passive immunization.

VEHICLE HAVING AN ARTICULATED JOINT

A vehicle comprising an articulated joint and a sensor arranged on the articulated joint and configured to detect a lateral area of the vehicle. The sensor is configured to be swiveled in order to change a sensed area. 1. A vehicle comprising:an articulated joint; anda sensor arranged on the articulated joint and configured to detect a lateral area of the vehicle,wherein the sensor is configured to be swiveled in order to change a sensed area.2. The vehicle according to claim 1 , wherein the sensor is configured to be swiveled based on an angle of articulation of the articulated joint.3. The vehicle according to claim 1 , wherein the sensor is configured to be swiveled based on a speed of travel of the vehicle.4. The vehicle according to claim 3 , wherein the sensor is arranged on a front outer area of the vehicle and a second sensor is arranged on a second front outer area of the vehicle claim 3 , and at a driving speed greater than zero claim 3 , the sensors are configured to be swiveled in such a manner that an overlapping area arises in which sensed areas of the sensor and of the second sensor overlap claim 3 , as a result of which a three-dimensional image can be detected.5. The vehicle according to claim 3 , wherein the sensor is arranged on a front outer area of the vehicle and a second sensor is arranged on a second front outer area of the vehicle claim 3 , wherein when the vehicle is stationary claim 3 , the sensors are configured to be swiveled in such a manner that there is no overlapping of the sensed areas of the sensor and of the second sensor claim 3 , as a result of which a two-dimensional image can be detected.6. The vehicle according to claim 1 , wherein the sensor is arranged on a first side of the vehicle and wherein a second sensor is arranged on a second side of the vehicle.7. The vehicle according to claim 1 , wherein the sensor is arranged on a rear end of a driver's cab of the vehicle.8. The vehicle according to claim 1 , wherein the sensor ...

Antibodies and related molecules that bind to 161P2F10B proteins

Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.

Specimen tip and tip holder assembly

A specimen tip holder assembly for mounting a specimen tip in a transmission electron microscope (TEM) is described. The specimen tip holder assembly comprises a tip holder for supporting a specimen tip. The tip holder is coupled to an elongate support for movement in a direction substantially perpendicular to the axis of the support. An actuator is mounted to the support for causing motion of the tip holder relative to the support.

MULTI-GEAR POWERSHIFT TRANSMISSION

A multi-gear powershift transmission for a working machine, in particular a forklift truck, which has a driveshaft (2) driven by a torque converter (1) such that, by way of fixed wheels (8, 13, 18, 23), loose wheels (10, 15, 20, 27) and shift clutches (4, 9, 19) arranged on countershafts (7, 12, 22) in a first transmission, at least two forward gears and two reverse gears can be engaged. The powershift transmission can be supplemented with a further countershaft (24) having a fixed wheel (25), a clutch (26) and a loose wheel (27) in order to produce a second powershift transmission in which three gears in the forward driving direction and three gears in the reverse driving direction are engageable.

Systems and methods for securing transactions with biometric information

A system that performs a transaction includes a mobile handset that has a biometric sensor. The biometric sensor detects a biometric from a user of the mobile handset. The mobile handset is associated with an account number. The system also includes an authentication processor configured to receive an authentication code from the mobile handset. The authentication processor uses the authentication code to authenticate the user and the user is granted access to an account corresponding to the account number when the user is authenticated by the authentication processor. The mobile handset may include a code generator that generates the authentication code. For example, the code may be generated from stored biometric information, a detected biometric, the account number, a phone number associated with the mobile handset, a serial number of the mobile handset, or a combination thereof. In one embodiment, the account number is the phone number.

Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers

A novel gene (designated 158P1D7) and its encoded protein are described. While 158P1D7 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including set forth in Table 1. Consequently, 158P1D7 provides a diagnostic and/or therapeutic target for cancers. The 158P1D7 gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit an immune response.

Methods of inducing an immune response

Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene products of a gene of FIG. 2 provide diagnostic, prognostic, prophylactic and/or therapeutic targets for cancer. A gene of FIG. 2 or fragment thereof, its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with a gene product of FIG. 2 can be used in active or passive immunization.

Anodized aluminum foil sheets and expanded aluminum foil (EAF) sheets and methods of making and using the same

Anodized aluminum foil sheets and expanded aluminum foil (EAF) and composites containing the same are disclosed. Methods of making anodized aluminum foil sheets and expanded aluminum foil (EAF) and composites containing the same are also disclosed. Methods of using anodized aluminum foil sheets and expanded aluminum foil (EAF) and composites containing the same are further disclosed.

Nucleic acid and corresponding protein entitled 151P3D4 useful in treatment and detection of cancer

A novel gene (designated 151P3D4) and its encoded protein, and variants thereof, are described wherein 151P3D4 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 151P3D4 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 151P3D4 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 151P3D4 can be used in active or passive immunization.

SANITARY COLD WATER TREATMENT SYSTEMS AND METHODS

A system and method for purifying and recycling cold wastewater is provided. Contaminated wastewater is supplied at a temperature no greater than 45° F. through an ultrafilter. The wastewater is fed through a reverse osmosis filter unit. Clean water is reused whereas reject is sent to disposal. Cold temperatures are preferably maintained throughout the treatment process. 1. A system for purifying and recycling cold wastewater , the system comprising:an ultrafiltration vessel receiving a cold wastewater maintained at a temperature no greater than 45° F. comprising an ultrafiltration inlet, an ultrafiltration outlet and an ultrafilter fluidly connected between the ultrafiltration inlet and the ultrafiltration outlet and wherein the ultrafiltration inlet is in fluid communication with an initial supply of the cold wastewater;a first reverse osmosis filter comprising a first reverse osmosis filter inlet and a first reverse osmosis filter outlet and wherein the first reverse osmosis filter inlet is in fluid communication with the ultrafiltration outlet; anda second reverse osmosis filter comprising a second reverse osmosis filter inlet and a second reverse osmosis filter outlet and wherein the second reverse osmosis filter outlet is in fluid communication with a return line.2. The system of claim 1 , wherein the system further comprises a granular activated carbon filter vessel comprising a granular activated carbon inlet claim 1 , a granular activated carbon filter claim 1 , and a granular activated carbon filter fluidly connected between the granular activated carbon filter inlet and the granular activated carbon outlet and wherein the granular activated carbon inlet is in fluid communication with the ultrafiltration outlet and the granular activated carbon inlet is in fluid communication with the first reverse osmosis filter inlet.3. The system of claim 1 , wherein the cold wastewater is maintained at a temperature no greater than 38° F.4. The system of claim 1 , ...

Determinate, delayed-ripening cherry tomato plants

The present invention provides determinate, delayed-ripening cherry tomato plants. The plants are hybrids derived from a determinate, non-ripening parental line.

Aircraft floor and interior panels using edge coated honeycomb

Aircraft floor and interior panels where core-skin bonding is improved between honeycomb and composite face sheets (skins) by applying a polyamide and/or rubber-containing adhesive to the edge of the honeycomb prior to bonding. Edge coating of the honeycomb allows one to reduce panel weight without reducing the performance parameters that are required for different types of aircraft floor and interior panels.

Methods of inducing an immune response

Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene products of a gene of FIG. 2 provide diagnostic, prognostic, prophylactic and/or therapeutic targets for cancer. A gene of FIG. 2 or fragment thereof, its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with a gene product of FIG. 2 can be used in active or passive immunization.

Clock adjustment

Circuits and methods are provided for clock adjustment. A method for clock adjustment includes receiving feedback clocks from independent ASIC modules. The method includes comparing the feedback clocks to a reference clock to generate phase measurement values. A common delay is removed from the phase measurement values to form normalized correction values. Target phase values and clock select values are selected using the normalized correction values. And, clock signals to independent ASIC modules are adjusted based on the target phase values and clock select values.

Antibodies and related molecules that bind to PSCA proteins

Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization. CROSS-REFERENCE TO RELATED APPLICATIONS ...

Vehicle having an articulated joint

A vehicle comprising an articulated joint and a sensor arranged on the articulated joint and configured to detect a lateral area of the vehicle. The sensor is configured to be swiveled in order to change a sensed area.

Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers

Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene products of a gene of FIG. 2 provide diagnostic, prognostic, prophylactic and/or therapeutic targets for cancer. A gene of FIG. 2 or fragment thereof, its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with a gene product of FIG. 2 can be used in active or passive immunization.

METHOD AND APPARATUS FOR DECANTING WINE

A method and apparatus (10) for transferring wine from a wine bottle (100) to a decanting receptacle (200) wherein the apparatus (10) includes: a pump unit (11) for introducing pressurized air into the interior of the wine bottle; a fluid withdrawal unit (12) for allowing the wine to flow out of the wine bottle (100) into a decanting receptacle (200); and, a support unit (13) for supporting the bottom of the wine bottle (100) at an angular inclination “α” to consolidate the lees (110) on one side of the bottle (100); wherein, a fluid withdrawal head member (50) is provided with a plurality of lateral passageways (55) disposed at a height of “h” above the bottom of the head member (50) to prevent the lees (110) from being transferred into the decanting receptacle.

Rubber-modified edge coating for honeycomb used in panels with composite face sheets

Core-skin bonding is improved between honeycomb and composite face sheets by applying a polyamide and/or rubber-containing adhesive to the edge of the honeycomb prior to bonding. Edge coating of honeycomb with a polyamide and/or rubber-containing adhesive is useful in further increasing the bond strength between honeycomb and prepreg face sheets, especially when the matrix resin of the prepreg is designed to adhere the prepreg to the honeycomb without the use of a separate structural adhesive.

Toilet tank plumbing fixture assembly

Described is a plumbing fixture assembly 10 for a toilet tank 14 comprising an upper portion 24 that connects with a valve 18, a lower portion 26 that is adapted for engagement with upper portion 24, and an attachment pipe 28 that connects at a first end 64 with lower portion 24 and at a distal end 66 with a supply line 16.

Method for ascertaining the target rotational speed of a drive machine of a work machine comprising a continuously variable transmission and a working hydraulic system

A process for determining a setpoint rotational speed of a work machine engine, having a continuously variable transmission, based on operation of power hydraulics. The setpoint rotational speed for highly productive operation is determined, without knowledge current operation of the power hydraulics, by a basic engine speed setting. With knowledge of the current operating state, the setpoint rotational speed is determined by the basic speed settings and low or high engine speed settings. The low speed setting alone determines setpoint rotational speeds that are lower than the basic speed setting or a combination of the low and basic speed settings. The high speed setting alone determines setpoint rotational speeds that are higher than the basic speed setting or a combination of the basic and high speed settings. The speed settings can comprise a setpoint rotational speed range of above a reciprocal transmission range of the variable transmission.

Transmission device with power splitting

A transmission with power branching, and the transmission, in a first drive range, transmits torque from the ring gear to a fixed wheel. In one branch, power is transmitted from a first to a second hydraulic unit which respectively operate as a pump and a motor. At one of the hydrostatic shafts, the mechanical and hydrostatic power are summed and transmitted to the drive output. In a second drive range, power coming from the planetary carrier is partially branched off to the ring gear and transmitted, via the gear wheels of the hydrostatic shaft, to the second hydraulic unit. From the second hydraulic unit, hydraulic power passes to the first hydraulic unit. In the process, the first hydraulic unit operates as a motor and the second hydraulic unit as a pump. From the second sun gear, power is transmitted to the double planetary gear and summed.

Edge coating for honeycomb used in panels with composite face sheets

Core-skin bonding is improved between honeycomb and composite face sheets by applying a nylon-based (polyamide) adhesive to the edge of the honeycomb prior to bonding. Edge coating of honeycomb with polyamide adhesives is useful in further increasing the bond strength between honeycomb and prepreg face sheets, especially when the matrix resin of the prepreg is designed to adhere the prepreg to the honeycomb.

CONTROL UNIT ADAPTED TO ACCOMMODATE DRONE

A control unit for a drone, said control unit comprising a protective case, a controller capable of remote operation of the drone and a space configured to receive the drone within said protective case for storage, wherein the drone is contained in its entirety within said protective case. 12. A control unit for a drone , said control unit comprising:{'b': '56', '(a) a protective case ;'}{'b': '6', '(b) a controller capable of remote operation of the drone; and'}{'b': 10', '56, '(c) a space configured to receive the drone within said protective case for storage,'}wherein the drone is contained in its entirety within said protective case.228610856. The control unit of claim 1 , further comprising a pair of joysticks functionally connected to said controller claim 1 , wherein said space is located between said pair of joysticks within said protective case .356326463256466. The control unit of claim 1 , wherein said protective case is substantially rectangular and further comprises a rear cover and said control unit further comprises at least one control button disposed on said rear cover of said protective case and said at least one control button is functionally connected to said controller .42545250545250. The control unit of claim 1 , further comprising a length claim 1 , a width and a height claim 1 , wherein said length measures up to about 108 mm claim 1 , said width measures up to about 86 mm and said height measures up to about 24 mm.522. The control unit of claim 1 , wherein said control unit includes a volume of no more than about 223 cubic cm.62818. The control unit of claim 1 , further comprising at least one joystick having a detachable handle .72221882256. The control unit of claim 1 , further comprising at least one post configured for storing at least one handle of a joystick claim 1 , wherein said post is disposed within said protective case .8256. The control unit of claim 1 , wherein at least a portion of said protective case is transparent.92305630 ...

Nucleic acid and corresponding protein entitled 161P5C5 useful in treatment and detection of cancer

A novel gene (designated 161P5C5) and its encoded protein, and variants thereof, are described wherein 161P5C5 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P5C5 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P5C5 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P5C5 can be used in active or passive immunization.

Portable speaker with suction cup

Nonlinear transformation of pixel width

Print data is resolved into pixels that each include a corresponding placement parameter. A nonlinear transfer function is applied to a width parameter for each pixel, and data is generated based on transformed width parameters and the corresponding placement parameters.

Aircraft floor and interior panels using edge coated honeycomb

Aircraft floor and interior panels where core-skin bonding is improved between honeycomb and composite face sheets (skins) by applying a polyamide and/or rubber-containing adhesive to the edge of the honeycomb prior to bonding. Edge coating of the honeycomb allows one to reduce panel weight without reducing the performance parameters that are required for different types of aircraft floor and interior panels.

Method of time-in-service reliability concern resolution

The present invention comprises a method determining a corrective design for a system component exhibiting time-in-service reliability concerns. The method comprises the steps of establishing a plurality of remote customer databases for collecting service data for a system component, receiving at a centralized database during a predetermined period of time at least one parameter representative of a failure rate for the system component based at least in part on the service data and determining if the at least one parameter represents a system component defect. When the at least one parameter represents a system component defect, the method includes determining at least one failure mode of the system component based at least in part on the at least one received parameter and determining a corrective design for the system component based at least in part on the at least one failure mode.

Database processing and management

A data-retrieval system maintains a database of records with which it associates respective security keys. It uses those security keys as a basis for deciding whether to grant access to the records. It additionally maintains organizational information that lists relationships among positions within an organization. When a requestor requests access to a record in the database, the system associates zero or more positions with the requestor, typically by determining which position or positions within the organization the requestor occupies. It additionally determines which, if any, other positions within the organization bear a predetermined relationship to any such occupied position, and it assembles a key list that includes keys that it has associated with all such positions. The way in which the system determines whether to grant the requestor access to the record is to determine whether the security key associated with that record matches any key in the key list.

Multi-gear powershift transmission

A multi-gear powershift transmission for a working machine, in particular a forklift truck, which has a driveshaft (2) driven by a torque converter (1) such that, by way of fixed wheels (8, 13, 18, 23), loose wheels (10, 15, 20, 27) and shift clutches (4, 9, 19) arranged on countershafts (7, 12, 22) in a first transmission, at least two forward gears and two reverse gears can be engaged. The powershift transmission can be supplemented with a further countershaft (24) having a fixed wheel (25), a clutch (26) and a loose wheel (27) in order to produce a second powershift transmission in which three gears in the forward driving direction and three gears in the reverse driving direction are engageable.

Nucleic acid and corresponding protein entitled 162P1E6 useful in treatment and detection of cancer

A novel gene (designated 162P1E6) and its encoded protein, and variants thereof, are described wherein 162P1E6 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 162P1E6 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 162P1E6 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 162P1E6 can be used in active or passive immunization.

Nucleic acid and corresponding protein entitled 238P1B2 useful in treatment and detection of cancer

A novel gene (designated 238P1B2) and its encoded protein, and variants thereof, are described wherein 238P1B2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 238P1B2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 238P1B2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 238P1B2 can be used in active or passive immunization.

Edge coating for honeycomb used in panels with composite face sheets

Core-skin bonding is improved between honeycomb and composite face sheets by applying a nylon-based (polyamide) adhesive to the edge of the honeycomb prior to bonding. Edge coating of honeycomb with polyamide adhesives is useful in further increasing the bond strength between honeycomb and prepreg face sheets, especially when the matrix resin of the prepreg is designed to adhere the prepreg to the honeycomb.

Quadcopter

Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer

A novel gene (designated 213P1F11) and its encoded protein, and variants thereof, are described wherein 213P1F11 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 213P1F11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 213P1F11 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 213P1F11 can be used in active or passive immunization.

Reduced-size gaming machine with onboard camera and method of use

A gaming machine is approximately half the depth of and weighs substantially less than standard gaming machines, thus greatly reducing the floor space needed to house the gaming machine and allowing it to be hung from a wall to increase the versatility of its location and improve the comfort of a game player due to greater leg room beneath the machine. An onboard camera is in communication with onboard video screens, remote video screens and other accessories to provide methods of increased security surveillance, methods of expediting service of the machine when it malfunctions, and methods of promoting the use of the gaming machine and the establishment housing the machine.

Scaling an image

A method for scaling an image includes determining a plurality of lineweight values for a plurality of virtual scan lines. In addition, the method includes determining a normalization value using the plurality of lineweight values. The method further includes determining a pulse code value for a pixel in an actual scan line using the plurality of lineweight values, the normalization value, and pulse code values for pixels in the plurality of virtual scan lines.

Threaded fastener with predetermined torque

The invention relates to a threaded fastener. In particular, the invention relates to a threaded fastener such as a nut or a bolt. In an embodiment of the invention, a threaded fastener in the form of a nut (10) is disclosed. The nut comprises a main body portion (12); a lip portion (14) extending from the main body portion; and a recess (16) formed in the main body portion adjacent the lip portion. The recess is shaped to receive at least part of the deformable lip portion when a mating torque is applied to the fastener causing the deformable lip portion to deform. In this fashion, when the fastener is used to clamp two or more components together, such as flanges (20, 22) on adjacent pipe sections, the lip portion encounters a surface of the component that the fastener is being used to clamp against. As the fastener is torqued-up to a desired level, to provide a determined mating force, the lip portion is deformed into the recess in the main body portion.

Systems and methods for biometric authentication

In one embodiment, an authentication system includes: a sensor for sensing a biometric and for providing a first code in response to sensing the biometric; and a processor for evaluating the first code to authenticate a user of the sensor independent of said sensor sensing the biometric. The biometric may be one or more of a group consisting of: retinal information; fingerprint information; ocular information; DNA; veinal information; arterial information; voice information; and pulmonary information. The processor may include a code generator to generate a second code for evaluating the first code. The processor may also include a comparator for comparing the first code and the second code to authenticate the user.

Specimen tip and tip holder assembly

A specimen tip holder assembly for mounting a specimen tip in a transmission electron microscope (TEM) is described. The specimen tip holder assembly comprises a tip holder for supporting a specimen tip. The tip holder is coupled to an elongate support for movement in a direction substantially perpendicular to the axis of the support. An actuator is mounted to the support for causing motion of the tip holder relative to the support.

Coating for a chainsaw chain

An extended-wear chain for a chainsaw, for example, with the chain having a coating that improves one or more wear characteristics of the chain. The coating preferrably includes one or more of titanium, zirconium, a titanium compound, or a zirconium compound. The coating can be deposited by using a physical vapor deposition process, for example.

Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer

A novel gene 0161P2F10B (also designated 161P2F10B) and its encoded protein, and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberranty expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.

Collapsible cargo organizer

Described is a cargo apparatus (10) including a base (16) having at least one end (30) and at least one side (28), with the at least one end having at least one laterally inside post (20) extending therefrom, and with the at least one side having at least one laterally outside post (18) extending therefrom. At least one end bracket (24) and at least one side bracket (22) are pivotably and translatably mounted to the base, wherein the brackets each have at least one support leg (38, 44) with a mounting end (42, 48). The mounting end pivotably mounts to its respective post on the base between open and closed positions and also translatably mounts to its respective post between an unlocked position distal the post and a locked position proximal the post, whereby the apparatus is collapsible to a closed portable position, and is foldable to a sturdy, open position.

Controller dock

Nano camera drone

Methods of inducing an immune response

Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene products of a gene of FIG. 2 provide diagnostic, prognostic, prophylactic and/or therapeutic targets for cancer. A gene of FIG. 2 or fragment thereof, its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with a gene product of FIG. 2 can be used in active or passive immunization.

Edge coating for honeycomb used in panels with composite face sheets

Core-skin bonding is improved between honeycomb and composite face sheets by applying a nylon-based (polyamide) adhesive to the edge of the honeycomb prior to bonding. Edge coating of honeycomb with polyamide adhesives is useful in further increasing the bond strength between honeycomb and prepreg face sheets, especially when the matrix resin of the prepreg is designed to adhere the prepreg to the honeycomb.

Method of time-in-service reliability concern resolution

The present invention comprises a method determining a corrective design for a system component exhibiting time-in-service reliability concerns. The method comprises the steps of establishing a plurality of remote customer databases for collecting service data for a system component, receiving at a centralized database during a predetermined period of time at least one parameter representative of a failure rate for the system component based at least in part on the service data and determining if the at least one parameter represents a system component defect. When the at least one parameter represents a system component defect, the method includes determining at least one failure mode of the system component based at least in part on the at least one received parameter and determining a corrective design for the system component based at least in part on the at least one failure mode.

Antibodies and related molecules that bind to PSCA proteins

Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.

ROTATABLE STAGE

A rotatable stage for an analytical apparatus. The rotatable stage has a stator, a heat exchanger in thermal connection with the stator, a rotor and a bearing located between the stator and the rotor. The bearing provides a thermal connection between the stator and rotor. 1. A rotatable stage for an analytical apparatus , the rotatable stage comprising:a stator;a heat exchanger in thermal connection with the stator;a rotor; anda bearing located between the stator and the rotor, the bearing providing a thermal connection between the stator and rotor.2. A rotatable stage according to claim 1 , wherein the bearing comprises a material having a thermal conductivity of greater than about 170 WmK.3. A rotatable stage according to any preceding claim claim 1 , wherein the bearing is configured to provide multiple points of contact between the bearing and the stator and multiple points of contact between the bearing and the rotor.4. A rotatable stage according to claim 3 , wherein the bearing is configured to provide at least 12 points of contact between the bearing and the stator and at least 12 points between the bearing and the rotor.5. A rotatable stage according to any one of the preceding claims claim 3 , wherein the bearing comprises one continuous component.6. A rotatable stage according to any one of the preceding claims claim 3 , wherein the bearing comprises a coiled spring.7. A rotatable stage according to claim 6 , wherein the coiled spring comprises a canted coiled spring.8. A rotatable stage according to any one of the preceding claims claim 6 , wherein the material of the bearing comprises at least one of copper claim 6 , phosphor claim 6 , bronze claim 6 , and CuBe.9. A rotatable stage according to any preceding claim claim 6 , wherein the heat exchanger comprises a gas tube configured to receive cooled gas.10. A rotatable stage according to any of to claim 6 , wherein the heat exchanger comprises a thermally conductive braid.11. A rotatable stage according ...

Rubber-modified edge coating for honeycomb used in panels with composite face sheets

Core-skin bonding is improved between honeycomb and composite face sheets by applying a polyamide and/or rubber-containing adhesive to the edge of the honeycomb prior to bonding. Edge coating of honeycomb with a polyamide and/or rubber-containing adhesive is useful in further increasing the bond strength between honeycomb and prepreg face sheets, especially when the matrix resin of the prepreg is designed to adhere the prepreg to the honeycomb without the use of a separate structural adhesive.

Nucleic acid and corresponding protein entitled 238P1B2 useful in treatment and detection of cancer

A novel gene (designated 238P1B2) and its encoded protein, and variants thereof, are described wherein 238P1B2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 238P1B2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 238P1B2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 238P1B2 can be used in active or passive immunization.

THREADED FASTENER WITH PREDETERMINED TORQUE

The invention relates to a threaded fastener. In particular, the invention relates to a threaded fastener such as a nut or a bolt. In an embodiment of the invention, a threaded fastener in the form of a nut (10) is disclosed. The nut comprises a main body portion (12); a lip portion (14) extending from the main body portion; and a recess (16) formed in the main body portion adjacent the lip portion. The recess is shaped to receive at least part of the deformable lip portion when a mating torque is applied to the fastener causing the deformable lip portion to deform. In this fashion, when the fastener is used to clamp two or more components together, such as flanges (20, 22) on adjacent pipe sections, the lip portion encounters a surface of the component that the fastener is being used to clamp against. As the fastener is torqued-up to a desired level, to provide a determined mating force, the lip portion is deformed into the recess in the main body portion.

Nucleic acid and corresponding protein entited 125P5C8 useful in treatment and detection of cancer

A novel gene (designated 125P5C8) and its encoded protein, and variants thereof, are described wherein 125P5C8 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 125P5C8 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 125P5C8 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 125P5C8 can be used in active or passive immunization.

Nucleic acids and corresponding proteins entitled 158P3D2 useful in treatment and detection of cancer

A novel gene 158P3D2 and its encoded protein, and variants thereof, are described wherein 158P3D2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 158P3D2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 158P3D2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 158P3D2 can be used in active or passive immunization.

Biological products

There are disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human KDR. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases in which VEGF and/or KDR are implicated.

ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS

Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer. 1. An antibody drug conjugate comprising an antibody or antigen binding fragment conjugated to monomethyl auristatin E (MMAE) , wherein the antibody or fragment comprises the heavy chain variable region consisting of the amino acid sequence ranging from 20E to the 136S of SEQ ID NO:7 and the light chain variable region consisting of the amino acid sequence ranging from 23D to the 130R SEQ ID NO:8.2. The antibody drug conjugate of claim 1 , wherein the antibody comprises the heavy chain consisting of the amino acid sequence ranging from 20E to the 466K of SEQ ID NO:7 and the light chain consisting of the amino acid sequence ranging from 23D to the 236C of SEQ ID NO:8.3. An antibody drug conjugate comprising an antibody or fragment conjugated to monomethyl auristatin E (MMAE) claim 1 , wherein the antibody or fragment comprises the heavy chain variable region consisting of the amino acid sequence of the heavy chain variable region of an antibody produced by a hybridoma deposited under American Type Culture Collection (ATCC) Accession No. PTA-11267 claim 1 , and the light chain variable region consisting of the amino acid sequence of the light chain variable region of an antibody produced by a hybridoma deposited under ATCC Accession No. PTA-11267.4. The antibody drug conjugate of claim 3 , wherein the antibody comprises the heavy chain consisting of the amino acid sequence of the heavy chain of an antibody produced by a hybridoma deposited under ATCC. Accession No. PTA-11267 claim 3 , and the light chain consisting of the amino acid sequence of the light chain of an antibody produced by a hybridoma deposited under ATCC. Accession No. ...

Nucleic acids and corresponding proteins entitled 158p3d2 useful in treatment and detection of cancer

A novel gene 158P3D2 and its encoded protein, and variants thereof, are described wherein 158P3D2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 158P3D2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 158P3D2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 158P3D2 can be used in active or passive immunization.

ANTIBODIES THAT BIND TO PSCA PROTEINS FOR DIAGNOSIS OF CANCER

Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization. 1. A monoclonal antibody or antigen binding fragment thereof comprising an antigen binding site that binds specifically to a PSCA protein comprising the amino acid sequence of SEQ ID NO:2, and wherein the monoclonal antibody comprises the amino acid sequence of the Vregion of SEQ ID NO: 35 and the Vregion of SEQ ID NO: 37. This patent application is a continuation of U.S. patent application Ser. No. 13/094,730, filed 26 Apr. 2011, now U.S. Pat. No. 8,278,424, which is a continuation of No. 12/397,992, filed 4 Mar. 2009, now U.S. Pat. No. 8,013,128, which is a divisional of U.S. patent application Ser. No. 11/131,648, filed 17 May 2005, now U.S. Pat. No. 7,595,379, issued 29 Sep. 2009, which claims the benefit of priority of U.S. Provisional Patent Application No. 60/616,381, filed 5 Oct. 2004; U.S. Provisional Patent Application No. 60/617,881, filed 12 Oct. 2004; and U.S. Provisional Patent Application No. 60/621,310, filed 21 Oct. 2004; U.S. Provisional Patent Application No. 60/633,077, filed 2 Dec. 2004; and U.S. Provisional Patent Application No. 60/672,000, filed 14 Apr. 2005; which is a continuation-in-part of pending U.S. patent application Ser. No. 10/857,484, filed 28 May 2004, now U.S. Pat. No. 7,622,564, issued 24 Nov. 2009, which claims priority to U.S. Provisional Patent Application No. 60/475,064, filed 30 May 2003. This application is also related to PCT ...

Optical tracking vehicle control system and method

A vehicle control system having a controller and a spatial database adapted to provide spatial data to the controller at control speed. The spatial data provided from the spatial database to the controller includes images collected from an optical sensor subsystem in addition to other data collected by a variety of sensor types, including a GNSS or inertial measurement system. The spatial data received by the controller from the database forms at least part of the control inputs that the controller operates on to control the vehicle. The advantage provided by the present invention allows control system to “think” directly in terms of spatial location. A vehicle control system in accordance with one particular embodiment of the invention comprises a task path generator, a spatial database, at least one external spatial data receiver, a vehicle attitude compensation module, a position error generator, a controller, and actuators to control the vehicle.

NUCLEIC ACID AND CORRESPONDING PROTEIN NAMED 158P1D7 USEFUL IN THE TREATMENT AND DETECTION OF BLADDER AND OTHER CANCERS

The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof. 1. A method for detection , the method comprising:providing a test sample, anddetermining an expression level of a protein in the test sample, wherein the determining is achieved by measuring specific binding of a binding partner to the protein in the test sample,wherein the binding partner is a substance that specifically binds to a protein comprising the amino acid sequence of SEQ ID NO: 3.2. The method of claim 1 , which further comprises:providing a normal sample;determining an expression level of the protein in the normal sample, wherein the determining is achieved by measuring specific binding of the binding partner to the protein in the normal sample; andcomparing the expression levels of the protein detected in the test sample and the normal sample.3. The method of claim 1 , wherein the binding partner is an antibody or antigen binding fragment thereof that specifically binds to a protein comprising the amino acid sequence of SEQ ID NO: 3.4. The method of claim 3 , wherein the antibody or fragment is monoclonal.5. The method of claim 1 , wherein the test sample is a bladder test sample.6. The method of claim 2 , wherein the normal sample is a normal bladder sample.7. A method to detect the presence of malignancy in a tissue claim 2 , which method comprises:contacting said tissue with an antibody or antigen binding fragment thereof that binds specifically to a protein comprising amino acid sequence of SEQ ID NO: 3 under conditions wherein a complex is formed of said antibody or antigen binding fragment thereof with a protein present in said tissue, and,detecting the presence of said complex,wherein the presence of said complex indicates the presence of malignancy in said ...

ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS

Antibody drug conjugates (ADC's) that bind to 24P4C12 protein and variants thereof are described herein. 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer. 1. A method for inhibiting growth of a cancer cell in a human subject , comprising:administering to the subject an effective amount of an antibody drug conjugate, wherein the conjugate comprises an antibody or antigen binding fragment thereof conjugated to monomethyl auristatin E (MMAE), and wherein the antibody or fragment thereof comprises a heavy chain variable region amino acid sequence of SEQ ID NO: 20, from residue 20 to 143, and a light chain variable region amino acid sequence of SEQ ID NO: 22, from residue 23 to 130.2. The method of claim 1 , wherein the antibody or antigen binding fragment thereof comprises the heavy chain amino acid sequence of SEQ ID NO: 20 claim 1 , from residue 20 to 469 and the light chain amino acid sequence of SEQ ID NO: 22 claim 1 , from residue 23 to 2363. The method of claim 1 , wherein the cancer cell is a prostate cancer cell.4. The method of claim 1 , wherein the cancer cell is a gastric cancer cell.5. The method of claim 1 , wherein the cancer cell is a pancreatic cancer cell.6. The method of claim 1 , wherein the cancer is ovarian cancer.7. The method of claim 1 , further comprising administering radiotherapy to the subject.8. The method of claim 1 , further comprising administering a chemotherapeutic agent other than the conjugate to the subject.9. A method for inhibiting growth of a cancer cell in a human subject claim 1 , comprising:administering to the subject an effective amount of an antibody drug conjugate, wherein the conjugate comprises an antibody or antigen binding fragment thereof conjugated to monomethyl auristatin E (MMAE), and wherein the antibody or fragment thereof comprises ...

NUCLEIC ACID AND CORRESPONDING PROTEIN NAMED 158P1D7 USEFUL IN THE TREATMENT AND DETECTION OF BLADDER AND OTHER CANCERS

The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof. 1. An antibody drug conjugate , comprising:an antibody or antigen binding fragment thereof conjugated to a cytotoxic agent, wherein the antibody or antigen binding fragment thereof binds to a protein consisting of the amino acid sequence of SEQ ID NO: 3.2. The antibody drug conjugate of claim 1 , wherein the antibody or fragment is monoclonal.3. The antibody drug conjugate of claim 1 , wherein the antibody or fragment is a recombinant protein.4. The antibody drug conjugate of claim 3 , wherein the antibody or fragment is a single chain monoclonal antibody or fragment thereof.5. The antibody drug conjugate of claim 1 , wherein the antibody or fragment is an Fab claim 1 , F(ab′) claim 1 , or Fv fragment.6. The antibody drug conjugate of claim 1 , wherein the antibody or fragment is a human antibody or fragment.7. The antibody drug conjugate of claim 1 , wherein the cytotoxic agent is selected from the group consisting of radioactive isotopes claim 1 , chemotherapeutic agents claim 1 , and toxins.8. The antibody drug conjugate of claim 7 , wherein the cytotoxic agent is a radioactive isotope selected from the group consisting of At claim 7 , I claim 7 , I claim 7 , Y claim 7 , Re claim 7 , Re claim 7 , Sm claim 7 , Bi claim 7 , P and radioactive isotopes of Lu.9. The antibody drug conjugate of claim 7 , wherein the cytotoxic agent is a chemotherapeutic agent selected from the group consisting of paclitaxel claim 7 , actinomycin claim 7 , mitomycin claim 7 , etoposide claim 7 , tenoposide claim 7 , vincristine claim 7 , vinblastine claim 7 , colchicine claim 7 , gelonin claim 7 , and calicheamicin.10Pseudomonas. The antibody drug conjugate of claim 7 , wherein the cytotoxic agent is a ...

ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS

Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer. 1. A 191P4D12 antibody or antigen binding fragment thereof wherein the antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising complementarity determining regions (CDRs) having the amino acid sequences of the heavy chain variable region CDRs set forth in SEQ ID NO:7 and a light chain variable region comprising CDRs having the amino acid sequences of the light chain variable region CDRs set forth in SEQ ID NO:8.2. The antigen binding fragment of claim 1 , wherein the fragment is an Fab claim 1 , F(ab′)2 claim 1 , Fv or scFv fragment.3. The antibody of claim 1 , wherein the antibody is a fully human antibody.4. The antibody of claim 1 , wherein the antibody is recombinantly produced.5. An antibody drug conjugate comprising the antibody or antibody binding fragment of .6. The antibody drug conjugate of wherein the cytotoxic agent is monomethyl auristatin E.7. A pharmaceutical composition comprising the antibody drug conjugate of .8. The pharmaceutical composition of wherein the cytotoxic agent is monomethyl auristatin E.9. A method for treating cancer in a subject claim 5 , comprising administering to said subject an antibody drug conjugate of .10. The method of wherein the cytotoxic agent is monomethyl auristatin E.11. The method of wherein the cancer is pancreatic cancer claim 9 , lung cancer claim 9 , bladder cancer claim 9 , or breast cancer. This application is a continuation of U.S. patent application Ser. No. 13/249,111, filed Sep. 29, 2011, which claims the benefit of priority from U.S. Provisional Patent Application No. 61/387,933, filed Sep. 29, 2010. The contents of each application ...

MODULAR TERMINAL ASSEMBLY FOR WIRELESS TRANSMITTERS

A terminal module is configured to fit inside an internal power source receptacle in a housing of a process field device, and comprises a wired power source connection, power conditioning electronics, and a field device connection. The wired power source connection is configured to receive power from an external source. The power conditioning electronics are capable of conditioning power from the wired power source connection for reception by the industrial field device. The field device connection is configured to provide power conditioned by the power conditioning electronics to the process field device via a terminal configured to receive and mate with the internal power source. 1. A wireless process field device assembly comprising:a process sensor which senses a process parameter;a processor configured to produce a process signal representing the sensed process parameter;a wireless transceiver configured to transmit the process signal;a housing which surrounds and protects the processor, and which is configured to receive an internal power source in a receptacle within the housing;a terminal block located inside the housing and configured to route DC power from the internal power source to the processor and the wireless transceiver; anda terminal module with power conditioning electronics, the terminal module configured to fit into the housing receptacle and interface with the terminal block in the place of the internal power source, and to provide conditioned power to the terminal block from a wired connection to an external power source.2. The wireless process field device assembly of claim 1 , wherein the terminal block is a removable module which detachably fastens into the housing.3. The wireless process field device assembly of claim 1 , wherein the power conditioning electronics comprise a DC rectifier.4. The wireless process field device assembly of claim 1 , wherein the power conditioning electronics limit voltage and/or current transmitted to the ...

NUCLEIC ACID AND CORRESPONDING PROTEIN NAMED 158P1D7 USEFUL IN THE TREATMENT AND DETECTION OF BLADDER AND OTHER CANCERS

The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof. 1. A method for detection , the method comprising:providing a test sample, anddetermining an expression level of a protein in the test sample, wherein the determining is achieved by measuring specific binding of a binding partner to the protein in the test sample,wherein the binding partner is a substance that specifically binds to a protein comprising the amino acid sequence of SEQ ID NO: 3.2. The method of claim 1 , which further comprises:providing a normal sample;determining an expression level of the protein in the normal sample, wherein the determining is achieved by measuring specific binding of the binding partner to the protein in the normal sample; andcomparing the expression levels of the protein detected in the test sample and the normal sample.3. The method of claim 1 , wherein the binding partner is an antibody or antigen binding fragment thereof that specifically binds to a protein comprising the amino acid sequence of SEQ ID NO: 3.4. The method of claim 3 , wherein the antibody or fragment is monoclonal.5. The method of claim 1 , wherein the test sample is a bladder test sample.6. The method of claim 2 , wherein the normal sample is a normal bladder sample.7. A method to detect the presence of malignancy in a tissue claim 2 , which method comprises:contacting said tissue with an antibody or antigen binding fragment thereof that binds specifically to a protein comprising amino acid sequence of SEQ ID NO: 3 under conditions wherein a complex is formed of said antibody or antigen binding fragment thereof with a protein present in said tissue, and,detecting the presence of said complex,wherein the presence of said complex indicates the presence of malignancy in said ...

NUCLEIC ACID AND CORRESPONDING PROTEIN NAMED 158P1D7 USEFUL IN THE TREATMENT AND DETECTION OF BLADDER AND OTHER CANCERS

The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof. 1. An antibody drug conjugate , comprising:an antibody or antigen binding fragment thereof conjugated to a cytotoxic agent, wherein the antibody or antigen binding fragment thereof binds to a protein consisting of the amino acid sequence of SEQ ID NO: 3.2. The antibody drug conjugate of claim 1 , wherein the antibody or fragment is monoclonal.3. The antibody drug conjugate of claim 1 , wherein the antibody or fragment is a recombinant protein.4. The antibody drug conjugate of claim 3 , wherein the antibody or fragment is a single chain monoclonal antibody or fragment thereof.5. The antibody drug conjugate of claim 1 , wherein the antibody or fragment is an Fab claim 1 , F(ab′) claim 1 , or Fv fragment.6. The antibody drug conjugate of claim 1 , wherein the antibody or fragment is a human antibody or fragment.7. The antibody drug conjugate of claim 1 , wherein the cytotoxic agent is selected from the group consisting of radioactive isotopes claim 1 , chemotherapeutic agents claim 1 , and toxins.8. The antibody drug conjugate of claim 7 , wherein the cytotoxic agent is a radioactive isotope selected from the group consisting of At claim 7 , I claim 7 , I claim 7 , Y claim 7 , Re claim 7 , Re claim 7 , Sm claim 7 , Bi claim 7 , P and radioactive isotopes of Lu.9. The antibody drug conjugate of claim 7 , wherein the cytotoxic agent is a chemotherapeutic agent selected from the group consisting of paclitaxel claim 7 , actinomycin claim 7 , mitomycin claim 7 , etoposide claim 7 , tenoposide claim 7 , vincristine claim 7 , vinblastine claim 7 , colchicine claim 7 , gelonin claim 7 , and calicheamicin.10Pseudomonas. The antibody drug conjugate of claim 7 , wherein the cytotoxic agent is a ...

NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER

A novel gene 0161P2F10B (also designated 161P2F10B) and its encoded protein, and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization. 1. An isolated antibody or antigen binding fragment thereof that immunospecifically binds to an epitope on a 161P2F10B protein comprising the amino acid sequence of SEQ ID NO: 17. This application is a continuation of U.S. patent application Ser. No. 13/153,336, filed Jun. 3, 2011, now U.S. Pat. No. 8,562,989, issuing Oct. 22, 2013, which is a divisional of U.S. patent application Ser. No. 12/641,261, filed Dec. 17, 2009, now U.S. Pat. No. 7,977,062, issued Jul. 12, 2011, which is a divisional of U.S. patent application Ser. No. 11/655,822, filed Jan. 19, 2007, now U.S. Pat. No. 7,667,018, issued Feb. 23, 2010, which is a divisional of U.S. patent application Ser. No. 10/291,241, filed Nov. 7, 2002, now U.S. Pat. No. 7,226,594, issued Jun. 5, 2007, which is a continuation-in-part of U.S. patent application Ser. No. 10/062,109, filed Jan. 31, 2002, now U.S. Pat. No. 7,067,130, issued Jun. 27, 2006, which is a continuation of U.S. patent application Ser. No. 10/005,480, filed Nov. 7, 2001, now abandoned. The contents of each application listed in this paragraph are fully incorporated by reference herein for all purposes.The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing (file name: 511582006208SeqList.txt, date recorded: Oct. 21, 2013, size: ...

ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS

Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer. 1. An antibody drug conjugate comprising an antibody or antigen binding fragment to monomethyl auristatin E (MMAE) , wherein the antibody or fragment comprises the heavy chain variable region consisting of the amino acid sequence ranging from 1Q to the 120S of SEQ ID NO: 7 and the light chain variable consisting of the amino acid sequence ranging from 1D to the 113R SEQ ID NO: 8.2. The antibody drug conjugate of claim 1 , wherein the antibody comprises the heavy chain consisting of the amino acid sequence ranging from 1Q to the 446K of SEQ ID NO: 7 and the light chain consisting of the amino acid sequence ranging from 1D to the 219C of SEQ ID NO: 8.3. An antibody drug conjugate comprising an antibody or fragment to conjugated to monomethyl auristatin E (MMAE) claim 1 , wherein the antibody or fragment comprises the heavy chain variable region consisting of the amino acid sequence of the heavy chain variable region of an antibody produced by a Chinese Hamster Ovary (CHO) cell deposited under American Type Culture Collection (ATCC) Accession No. PTA-13102 claim 1 , and the light chain variable region consisting of the amino acid sequence of the light chain variable region of an antibody produced by a Chinese Hamster Ovary (CHO) cell deposited under ATCC Accession No. PTA-13102.4. The antibody drug conjugate of claim 3 , wherein the antibody comprises the heavy chain consisting of the amino acid sequence of the heavy chain of an antibody produced by a Chinese Hamster Ovary (CHO) cell deposited under ATCC. Accession No. PTA-13102 claim 3 , and the light chain consisting of the amino acid sequence of the ...

DIVERSITY ANTENNA HOUSING

A wireless device comprises a plurality of diverse antennas, an accelerometer configured to determine an orientation of the wireless device, and a processor. The processor is configured to initially select a primary link configuration based on the determined orientation of the wireless device. The primary link configuration designates one or more of the plurality of diverse antennas and one or more diverse antennas of another wireless device configured to transmit the payload messages. The processor is further configured to receive payload messages using the primary link configuration, record a received signal strength indication (RSSI) value for the received payload messages, and periodically test RSSI for alternative link configurations. The processor compares RSSI between the primary link configuration and the alternative link configuration, and revises the primary link configuration if the comparison indicates that the alternative link configuration RSSI is greater than primary link configuration RSSI. 1. A wireless device comprising:a plurality of diverse antennas;an accelerometer configured to provide a signal from which orientation of the wireless device can be determined; and initially select a primary link configuration based on the determined orientation of the wireless device, the primary link configuration designating one or more of the plurality of diverse antennas and one or more antennas of another wireless device configured to transmit the payload messages;', 'receive payload messages using the primary link configuration, and record a received signal strength indication (RSSI) value for the received payload messages;', 'periodically test RSSI for alternative link configurations;', 'compare RSSI between the primary link configuration and the alternative link configuration; and', 'revise the primary link configuration when the comparison indicates that the alternative link configuration RSSI is greater than primary link configuration RSSI., 'a ...

COATINGS FOR RELATIVELY MOVABLE SURFACES

A device has a microelectromechanical system (MEMS) component with at least one surface and a coating disposed on at least a portion of the surface. The coating has a compound of the formula M(CnF2n+1Or), wherein M is a polar head group and wherein n≧2r. The value of n may range from 2 to about 20, and the value of r may range from 1 to about 10. The value of n plus r may range from 3 to about 30, and a ratio of n:r may have a value of about 2:1 to about 20:1. 1. A method of fabricating a microelectromechanical system (MEMS) device comprising:forming a MEMS component having a surface; and{'sub': n', '2n+1', 'r, 'coating at least a portion of the surface with a compound of the formula M(CFO), wherein M comprises a polar head group, and wherein n≧2r.'}2. The method of claim 1 , wherein the polar head group comprises a central atom having a coordination number of 3 claim 1 , 4 claim 1 , or 5.3. The method of claim 2 , wherein the polar head group comprises an oxygen atom bound to the central atom.4. The method of claim 3 , wherein the polar head group comprises a hydroxyl functional group bound to the central atom.5. The method of claim 1 , wherein the polar head group comprises at least one functional group selected from the group consisting of: a carboxylic acid functional group; a sulfonic acid functional group claim 1 , a phosphonic acid functional group claim 1 , an amide functional group claim 1 , and a hydroxamide functional group.6. The method of claim 1 , wherein n has a value ranging from 2 to about 20.7. The method of claim 1 , wherein r has a value ranging from 1 to about 10.8. The method of claim 1 , wherein n+r ranges from 3 to about 30.9. The method of claim 1 , wherein a ratio of n:r has a value of about 2:1 to about 20:1.10. The method of claim 1 , wherein the MEMS component comprises a digital micromirror device.11. The method of claim 1 , wherein the MEMS component comprises at least one of an actuator claim 1 , a motor claim 1 , an RF switch claim 1 ...

Method for carrying out cold-starting

A method for performing a cold start in a vehicle having a power-spat transmission with a hydrostatic element comprising hydrostatic units. Several cold-start steps are performed sequentially for a cold start, the length of at least one of the cold-start steps is adapted depending on a temperature representing the start temperature of the power-split transmission. A state of the power-split transmission deviating from the temperature of the power-split transmission is monitored, during the execution of at least one of the cold-start steps, and, depending on this state, a transition from the respective cold-start steps to the subsequent cold-start step is performed, thus adapting the length of time of the respective cold-start steps.

COATINGS FOR RELATIVELY MOVABLE SURFACES

A device comprises a MEMS component comprising at least one surface and a coating disposed on at least a portion of the surface. The coating comprises a compound of the formula M(CFO), wherein M comprises a polar head group, and wherein n≧2r. The value of n may range from 2 to about 20, and the value of r may range from 1 to about 10. The value of n plus r may range from 3 to about 30, and a ratio of n:r may have a value of about 2:1 to about 20:1. 1. A device comprising:a MEMS component comprising a surface; and{'sub': n', '2n+1', 'r, 'a coating disposed on at least a portion of the surface, wherein the coating comprises a compound of the formula M(CFO), wherein M comprises a polar head group, and wherein n≧2r.'}2. The device of claim 1 , wherein the polar head group comprises a central atom having a coordination number of 3 claim 1 , 4 claim 1 , or 5.3. The device of claim 2 , wherein the polar head group comprises an oxygen atom bound to the central atom.4. The device of claim 3 , wherein the polar head group comprises a hydroxyl functional group bound to the central atom.5. The device of claim 1 , wherein the polar head group comprises at least one functional group selected from the group consisting of: a carboxylic acid functional group; a sulfonic acid functional group claim 1 , a phosphonic acid functional group claim 1 , an amide functional group claim 1 , and a hydroxamide functional group.6. The device of claim 1 , wherein n has a value ranging from 2 to about 20.7. The device of claim 1 , wherein r has a value ranging from 1 to about 10.8. The device of claim 1 , wherein n+r ranges from 3 to about 30.9. The device of claim 1 , wherein a ratio of n:r has a value of about 2:1 to about 20:1.10. The device of claim 1 , wherein the MEMS component comprises a digital micromirror device.11. The device of claim 1 , wherein the MEMS component comprises at least one of an actuator claim 1 , a motor claim 1 , an RF switch claim 1 , a sensor claim 1 , a variable ...

NUCLEIC ACID AND CORRESPONDING PROTEIN NAMED 158P1D7 USEFUL IN THE TREATMENT AND DETECTION OF BLADDER AND OTHER CANCERS

The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof. 1. (canceled)2. A method of inhibiting growth of a cell which expresses a 158P1D7 protein , comprising:providing to the cell an antibody or antigen binding fragment thereof that specifically binds to the 158P1D7 protein, which comprises the amino acid sequence of SEQ ID NO: 3, wherein the antibody or antigen binding fragment thereof specifically binds to the protein within amino acid residues 25-45 or 274-285 of SEQ ID NO: 3, and wherein the cell expressing the protein is a bladder cell, whereby growth of the cell that expresses the protein is inhibited.3. The method of claim 2 , wherein the antibody or antigen binding fragment thereof specifically binds to the protein within amino acid residues 25-45 of SEQ ID NO: 3.4. The method of claim 2 , wherein the antibody or antigen binding fragment thereof specifically binds to the protein within amino acid residues 274-285 of SEQ ID NO: 3.5. The method of claim 2 , wherein the cell is a cancer cell.6. The method of claim 2 , wherein the antibody fragment is selected from the group consisting of an Fab claim 2 , F(ab′)2 claim 2 , Fv and sFv.7. The method of claim 2 , wherein the antibody or fragment thereof is labeled with an agent.8. The method of claim 7 , wherein the agent is a diagnostic agent or a cytotoxic agent.9. The method of claim 8 , wherein the cytotoxic agent is selected from the group consisting of radioactive isotopes claim 8 , chemotherapeutic agents and toxins.10. The method of claim 9 , wherein the radioactive isotope is selected from the group consisting of At claim 9 , I claim 9 , I claim 9 , Y claim 9 , Re claim 9 , Re claim 9 , Sm claim 9 , Bi claim 9 , P and radioactive isotopes of Lu.11. The method of claim 9 , ...

ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS

Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer. 1. (canceled)2. An anti-158P1D7 antibody or antigen binding fragment thereof , wherein the antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising an amino acid sequence at least 80% homologous to the heavy chain variable region amino acid sequence set forth in SEQ ID NO:7 and a light chain variable region comprising an amino acid sequence at least 80% homologous to the light chain variable region amino acid sequence set forth in SEQ ID NO:8 ,wherein the heavy chain complementarity determining region 1 (CDR-H1), CDR-H2, and CDR-H3 of the antibody or antigen binding fragment thereof are identical to the amino acid sequences of the respective CDR-H1, CDR-H2, and CDR-H3 in the heavy chain variable region sequence set forth in SEQ ID NO: 7 and the light chain complementarity determining region 1 (CDR-L1), CDR-L2, and CDR-L3 of the antibody or antigen binding fragment thereof are identical to the amino acid sequence of the respective CDR-L1, CDR-L2, and CDR-L3 in the light chain variable region sequence set forth in SEQ ID NO: 8, andwherein the CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 are determined by Kabat numbering scheme.3. The anti-158P1D7 antibody or antigen binding fragment thereof of claim 2 , wherein the antibody or fragment thereof comprises a heavy chain variable region comprising an amino acid sequence at least 85% claim 2 , 86% claim 2 , 87% claim 2 , 88% claim 2 , 89% claim 2 , 90% claim 2 , 91% claim 2 , 92% claim 2 , 93% claim 2 , 94% claim 2 , 95% claim 2 , 96% claim 2 , 97% claim 2 , 98% claim 2 , or 99% homologous to the heavy chain ...

Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer

A novel gene 0161P2F10B (also designated 161P2F10B) and its encoded protein, and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.

BACK REST ASSEMBLY

A back rest assembly includes a base assembly mountable adjacent a resting surface and a back rest having a supported side pivotably supported by the base assembly and an unsupported side spaced laterally apart from the supported side along a lateral axis. When the base assembly is mounted, the back rest is positionable over the resting surface and selectively pivotable about the lateral axis for adjusting an angular position of the back rest relative to the resting surface. 1. A back rest assembly for a bed having a horizontal resting surface extending laterally between a bed first side and a bed second side of the bed , the back rest assembly comprising:a) a base positionable underneath the resting surface for stabilizing the back rest assembly, the base extending laterally between a base first side for positioning on the bed first side and a base second side spaced apart from the base first side in a lateral direction, the base second side for positioning toward the bed second side;b) a riser supported by the base on the base first side and extending upwardly relative to the base, the riser positioned laterally outboard of the resting surface on the bed first side when the base is underneath the resting surface; andc) a back rest spaced vertically above the base, the back rest having a supported side laterally adjacent to and pivotably supported by the riser and an unsupported side spaced laterally apart from the supported side in the lateral direction toward the base second side, wherein when the base is underneath the resting surface, the back rest is positioned over the resting surface and is pivotable about a lateral first axis fixed relative to the riser between a horizontal position in which the back rest is oriented generally horizontally, and at least one inclined position in which the back rest is inclined relative to the resting surface for supporting a user's back.2. The back rest assembly of claim 1 , wherein the back rest assembly is free of any load ...

TRIMMER LINE WITH CENTERING FEATURE

A trimmer line for use with a trimmer head having an outer diameter and defining an axis of rotation. The trimmer line may include an elongated body having a first end, an opposite second end, and a center between the first end and the second end. The trimmer line also may also include indicia formed on the elongated body and spaced from the center point a distance greater than or equal to about half the outer diameter. 1. A trimmer line for use with a trimmer head having an outer diameter , the trimmer line comprising:an elongated body having a first end, an opposite second end, and a center between the first end and the second end;indicia formed on the elongated body and spaced from the center a distance greater than or equal to about half the outer diameter.2. The trimmer line of claim 1 , wherein the center is coincident a center of gravity of the elongated body.3. The trimmer line of claim 1 , wherein the center is spaced an equal distance from the first end and from the second end.4. The trimmer line of claim 1 , wherein the indicia includes first indicia and second indicia spaced from the first indicia a distance greater than or equal to about the outer diameter.5. The trimmer line of claim 1 , wherein the indicia is positioned on the body to be visible from outside the trimer head when the center of the body is substantially aligned with an axis of rotation of the trimmer head.6. The trimmer line of claim 1 , wherein the indicia includes a marking applied to the elongated body.7. The trimmer line of claim 6 , wherein the indicia includes a line printed on and extending circumferentially around an outer surface of the elongated body.8. The trimmer line of claim 1 , wherein the indicia includes a notch formed into the elongated body.9. A trimmer line for use with a trimmer head defining an axis of rotation claim 1 , the trimmer line comprising:an elongated body having a first end, an opposite second end, and a center between the first end and the second end;a ...

ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS

Antibody drug conjugates (ADC's) that bind to 161P2F10B protein are described herein. 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer. 1. An antibody drug conjugate, comprising an antibody or antigen binding fragment thereof that binds specifically to a 161P2F10B protein comprising the amino acid sequence of SEQ ID NO:2, wherein the antibody comprises the amino acid sequence of the Vregion of SEQ ID NO:7, from 20 to 142, and the Vregion of SEQ ID NO:8, from 20 to 127 and wherein said antibody is conjugated to monomethyl auristatin F (MMAF). This application is a continuation of U.S. application Ser. No. 13/022,905, filed on Feb. 8, 2011, now U.S. Pat. No. 8,609,902, which claims the benefit of priority to U.S. Provisional Application No. 61/302,489, filed on Feb. 8, 2010. The contents of these applications are hereby incorporated by reference in their entirety.Not applicable.The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing (file name: 511582006232SeqList.txt, date recorded: Nov. 26, 2013; size: 43,657 bytes).The invention described herein relates to antibody drug conjugates (ADCs) thereof that bind proteins, termed 161P2F10B. The invention further relates to prognostic, prophylactic and therapeutic methods and compositions useful in the treatment of cancers.Cancer is the second leading cause of human death next to coronary disease. Worldwide, millions of people die from cancer every year. In the United States alone, as reported by the American Cancer Society, cancer causes the death of well over a half-million people annually, with over 1.2 million new cases diagnosed per year. While deaths from heart disease have been declining significantly, those resulting from ...

NOVEL ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER

A novel gene 0161P2F10B (also designated 161P2F10B) and its encoded protein, and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization. 1. An isolated antibody or antigen binding fragment thereof that immunospecifically binds to an epitope on a 161P2F10B protein comprising the amino acid sequence of SEQ ID NO: 17. This application is a continuation of U.S. patent application Ser. No. 14/059,374, filed Oct. 21, 2013, now U.S. Pat. No. 8,846,043, issued on Sep. 30, 2014, which is a continuation of U.S. patent application Ser. No. 13/153,336, filed Jun. 3, 2011, now U.S. Pat. No. 8,562,989, issued Oct. 22, 2013, which is a divisional of U.S. patent application Ser. No. 12/641,261, filed Dec. 17, 2009, now U.S. Pat. No. 7,977,062, issued Jul. 12, 2011, which is a divisional of U.S. patent application Ser. No. 11/655,822, filed Jan. 19, 2007, now U.S. Pat. No. 7,667,018, issued Feb. 23, 2010, which is a divisional of U.S. patent application Ser. No. 10/291,241, filed Nov. 7, 2002, now U.S. Pat. No. 7,226,594, issued Jun. 5, 2007, which is a continuation-in-part of U.S. patent application Ser. No. 10/062,109, filed Jan. 31, 2002, now U.S. Pat. No. 7,067,130, issued Jun. 27, 2006, which is a continuation of U.S. patent application Ser. No. 10/005,480, filed Nov. 7, 2001, now abandoned. The contents of each application listed in this paragraph are fully incorporated by reference herein for all purposes.The content of the following submission on ASCII text file is incorporated herein by ...

Support Frame for Adjustable Blade Assembly

A support frame for supporting a blade on a machine is provided. The support frame includes a lower frame section including a first leg, a second leg and a transverse portion that extends between the first leg and the second leg. Each of the first and second legs has a respective end portion and the transverse portion carries a lower connecting element configured to connect to a blade. An upper frame section includes a first leg, a second leg and a transverse portion that extends between the first leg and the second leg, each of the first and second legs having a respective end portion. The end portions of the respective first legs of the lower frame section and the upper frame section are connected together and the respective transverse portions of the lower frame section and the upper frame section are spaced from each other. 1. A support frame for supporting a blade on a machine , the support frame comprising:a lower frame section including a first leg, a second leg and a transverse portion that extends between the first leg and the second leg, each of the first and second legs having a respective end portion and the transverse portion carrying a lower connecting element configured to connect to a blade; andan upper frame section including a first leg, a second leg and a transverse portion that extends between the first leg and the second leg, each of the first and second legs having a respective end portion;wherein the end portions of the respective first legs of the lower frame section and the upper frame section are connected together and the respective transverse portions of the lower frame section and the upper frame section are spaced from each other.2. The support frame of further including at least one brace extending between the transverse portion of the lower frame section and the transverse portion of the upper frame section.3. The support frame of wherein each of the lower frame section and the upper frame section have an upper wall claim 1 , a lower ...

NUCLEIC ACID AND CORRESPONDING PROTEIN NAMED 158P1D7 USEFUL IN THE TREATMENT AND DETECTION OF BLADDER AND OTHER CANCERS

The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof. 1. An antibody drug conjugate , comprising: an antibody or antigen binding fragment thereof conjugated to a cytotoxic agent , wherein the antibody or antigen binding fragment thereof binds to a protein consisting of the amino acid sequence of SEQ ID NO: 3.2. A method of inhibiting growth of a cancer cell which expresses a 158P1D7 protein , comprising providing an antibody or antigen binding fragment thereof that specifically binds to an epitope of the 158P1D7 protein , thereby inhibiting growth of the cancer cell ,wherein the 158P1D7 protein comprises the amino acid sequence of SEQ ID NO: 3;wherein the epitope of the 158P1D7 protein to which the antibody or antigen binding fragment thereof specifically binds is located within amino acid residues 25-45 or 274-285 of SEQ ID NO: 3, andwherein the cancer cell is a bladder cancer cell.3. A method of generating a mammalian immune response directed to a protein , the method comprising exposing a cell of the mammal's immune system to the protein , wherein the protein has an amino acid sequence selected from the group consisting of SEQ ID NO: 3 , 5 , 7 , 9 , 11 , and 13. This application is a continuation of U.S. application Ser. No. 14/612,190, filed on Feb. 2, 2015, which is a continuation of U.S. application Ser. No. 13/662,318, filed Oct. 26, 2012, now U.S. Pat. No. 8,945,570, which is a continuation of U.S. application Ser. No. 12/050,895, filed Mar. 18, 2008, now abandoned, which is a divisional application of U.S. application Ser. No. 10/776,773, filed Feb. 10, 2004, now U.S. Pat. No. 7,358,353, which claims the benefit of priority of U.S. Provisional Application No. 60/446,633, filed Feb. 10, 2003, and is a continuation-in-part of U ...

METHOD FOR ASCERTAINING THE TARGET ROTATIONAL SPEED OF A DRIVE MACHINE OF A WORK MACHINE COMPRISING A CONTINUOUSLY VARIABLE TRANSMISSION AND A WORKING HYDRAULIC SYSTEM

A process for determining a setpoint rotational speed of a work machine engine, having a continuously variable transmission, based on operation of power hydraulics. The setpoint rotational speed for highly productive operation is determined, without knowledge current operation of the power hydraulics, by a basic engine speed setting. With knowledge of the current operating state, the setpoint rotational speed is determined by the basic speed settings and low or high engine speed settings. The low speed setting alone determines setpoint rotational speeds that are lower than the basic speed setting or a combination of the low and basic speed settings. The high speed setting alone determines setpoint rotational speeds that are higher than the basic speed setting or a combination of the basic and high speed settings. The speed settings can comprise a setpoint rotational speed range of above a reciprocal transmission range of the variable transmission. 113-. (canceled)146174441. A process for determining a setpoint rotational speed (n_soll) of a prime mover () of a work machine () , having a continuously variable transmission () and power hydraulics () , as a function of an operating state of the power hydraulics () , the setpoint rotational speed (n_soll) being determined without knowledge of a current operating state of the power hydraulics () by basic engine speed settings , which is used to determine the setpoint rotational speeds (n_soll) , at which the work machine () operates with high productivity , the method comprising:{'b': '4', 'determining the setpoint rotational speed (n_soll), if the operating state of the power hydraulics () is known, taking into account the basic engine speed settings and at least additionally as a function of a low engine speed setting and a high engine speed setting;'}determining, with the low engine speed setting alone, lower setpoint speeds (n_soll) than the basic engine speed setting or a combination of the low engine speed setting ...

STRING TRIMMER HEAD

A trimmer head and a method for assembling a trimmer head. The trimmer head may generally include a housing rotatable about an axis; a receptacle in the housing to receive a portion of a trimmer line; and a locking member movable in a radial direction relative to the housing between a first position, in which the locking member engages the trimmer line to axially retain the trimmer line relative to the housing, and a second position, in which the trimmer line is movable relative to the receptacle. 1. A trimmer head for use with a trimmer , the trimmer head comprising:a housing rotatable about an axis;a receptacle in the housing to receive a portion of a trimmer line; anda locking member movable in a radial direction relative to the housing between a first position, in which the locking member engages the trimmer line to axially retain the trimmer line relative to the housing, and a second position, in which the trimmer line is movable relative to the receptacle.2. The trimmer head of claim 1 , wherein the trimmer line includes a hub and a cutting string claim 1 , wherein the receptacle receives the hub claim 1 , and wherein the locking member engages the hub.3. The trimmer head of claim 2 , wherein the trimmer line includes a hub and a plurality of cutting strings.4. The trimmer head of claim 2 , wherein the receptacle supports the hub for pivotable movement relative to the housing.5. The trimmer head of claim 2 , wherein the receptacle limits pivotal movement of the hub relative to the housing.6. The trimmer head of claim 2 , wherein the housing defines an opening through which the cutting string extends.7. The trimmer head of claim 6 , wherein the receptacle supports the hub for pivotable movement relative to the housing claim 6 , and wherein the opening includes a slot allowing pivoting movement of the cutting string relative to the housing.8. The trimmer head of claim 2 , wherein the hub includes a protrusion claim 2 , and wherein the receptacle receives the ...

ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS

Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer. 1. An antibody drug conjugate comprising an antibody or antigen binding fragment to monomethyl auristatin E (MMAE), wherein the antibody or fragment comprises the heavy chain variable region consisting of the amino acid sequence ranging from 1Q to the 120S of SEQ ID NO: 7 and the light chain variable consisting of the amino acid sequence ranging from 1D to the 113R SEQ ID NO: 8. This application is a continuation of U.S. application Ser. No. 13/975,214, filed 23 Aug. 2013, now U.S. Pat. No. 8,968,742, which claims priority to U.S. Provisional Patent Application No. 61/692,448, filed 23 Aug. 2012. All applications are herein incorporated by reference in their entirety for all purposes.The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing (file name: 511582505001SeqList.txt, date recorded: Jan. 28, 2015, size: 40,186 bytes.The invention described herein relates to antibodies, binding fragments, and antibody drug conjugates (ADCs) thereof, that bind proteins, termed 158P1D7. The invention further relates to prognostic, prophylactic and therapeutic methods and compositions useful in the treatment of cancers that express 158P1D7.Cancer is the second leading cause of human death next to coronary disease.Worldwide, millions of people die from cancer every year. In the United States alone, as reported by the American Cancer Society, cancer causes the death of well over a half-million people annually, with over 1.2 million new cases diagnosed per year. While deaths from heart disease have been ...

COATINGS FOR RELATIVELY MOVABLE SURFACES

A device has a microelectromechanical system (MEMS) component with at least one surface and a coating disposed on at least a portion of the surface. The coating has a compound of the formula M(CnF2n+1Or), wherein M is a polar head group and wherein n≧2r. The value of n may range from 2 to about 20, and the value of r may range from 1 to about 10. The value of n plus r may range from 3 to about 30, and a ratio of n:r may have a value of about 2:1 to about 20:1. 1. A method of protecting a device , the method comprising:receiving a MEMS component or semiconductor component; anddisposing a coating on a surface of the MEMS component or semiconductor component, wherein the coating comprises an amphiphilic compound comprising a hydrophilic head group bound to a hydrophobic tail, wherein the hydrophobic tail comprises a fluorinated carbon chain and at least one ether functional group disposed within the fluorinated carbon chain.2. The method of claim 1 , wherein the amphiphilic compound comprises a compound of the formula M(CFO) claim 1 , wherein M is the hydrophilic head group claim 1 , wherein (CFO) is the hydrophobic tail claim 1 , and wherein n≧2r.3. The method of claim 1 , wherein the hydrophobic tail comprises 1 to about 10 ether functional groups disposed within the fluorinated carbon chain.4. The method of claim 1 , wherein the hydrophobic tail comprises 2 to about 20 carbon atoms.5. The method of claim 1 , wherein the hydrophobic tail comprises a plurality of ether functional groups disposed within the fluorinated carbon chain claim 1 , and wherein a number of carbon atoms in the fluorinated carbon chain separating sequential ether groups ranges from 1-6 carbon atoms.6. The method of claim 1 , wherein the fluorinated carbon chain comprises a perfluorinated carbon chain.7. The method of claim 1 , wherein disposing the coating comprises performing a vapor deposition process.8. The method of claim 1 , further comprising forming a monolayer on the at least one surface ...

ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS

Antibody drug conjugates (ADC's) that bind to 161P2F10B protein are described herein. 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer. 1. An antibody drug conjugate, comprising an antibody or antigen binding fragment thereof that binds specifically to a 161P2F10B protein comprising the amino acid sequence of SEQ ID NO:2, wherein the antibody comprises the amino acid sequence of the Vregion of SEQ ID NO:7, from 20 to 142, and the Vregion of SEQ ID NO:8, from 20 to 127 and wherein said antibody is conjugated to monomethyl auristatin F (MMAF). This application is a continuation of U.S. application Ser. No. 14/106,444, filed on Dec. 13, 2013, now U.S. Pat. No. 9,308,278, which is a continuation of U.S. application Ser. No. 13/022,905, filed on Feb. 8, 2011, now U.S. Pat. No. 8,609,902, which claims the benefit of priority to U.S. Provisional Application No. 61/302,489, filed on Feb. 8, 2010. The contents of these applications are hereby incorporated by reference in their entirety.Not applicable.The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing (file name: 511582006233SeqList.txt, date recorded: Mar. 15, 2016; size: 43,691 bytes).The invention described herein relates to antibody drug conjugates (ADCs) thereof that bind proteins, termed 161P2F10B. The invention further relates to prognostic, prophylactic and therapeutic methods and compositions useful in the treatment of cancers.Cancer is the second leading cause of human death next to coronary disease. Worldwide, millions of people die from cancer every year. In the United States alone, as reported by the American Cancer Society, cancer causes the death of well over a half-million people annually, with over 1.2 million ...

ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS

Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer. 1. (canceled)2. An anti-158P1D7 antibody or antigen binding fragment thereof , wherein the antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising complementarity determining regions (CDRs) consisting of the amino acid sequences of the CDRs set forth in SEQ ID NO: 7 according to Kabat numbering and a light chain variable region consisting of the amino acid sequence ranging from position 1 to position 113 of SEQ ID NO: 8.3. The antigen binding fragment thereof of claim 2 , wherein the antigen binding fragment is an Fab claim 2 , F(ab′)2 claim 2 , Fv claim 2 , or scFv fragment.4. The anti-158P1D7 antibody or antigen binding fragment thereof of claim 2 , wherein the antibody or antigen binding fragment thereof is a fully human antibody or antigen binding fragment thereof.5. The anti-158P1D7 antibody or antigen binding fragment thereof of claim 2 , wherein the antibody or antigen binding fragment thereof is recombinantly produced.6. An antibody drug conjugate comprising the antibody or antibody binding fragment of conjugated to monomethyl auristatin E (MMAE) via a linker.7. The antibody drug conjugate of claim 6 , wherein the linker comprises valine-citrulline.9. The antibody drug conjugate of claim 8 , wherein the p ranges from 2 to 5.10. A pharmaceutical composition comprising a therapeutically effective amount of the antibody drug conjugate of and a pharmaceutically acceptable excipient.11. The pharmaceutical composition of claim 10 , wherein the composition is in a human unit dose form.12. A method of treating cancer in a subject claim 8 , comprising administering ...

ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS

Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer. 1. (canceled)3. The antibody drug conjugate of claim 2 , wherein the antibody or antigen binding fragment thereof comprises a heavy chain variable region consisting of the amino acid residue 20 to amino acid residue 136 of SEQ ID NO: 7 and a light chain variable region consisting of the amino acid sequence ranging from amino acid residue 23 to amino acid residue 130 of SEQ ID NO: 8.4. The antibody drug conjugate of claim 3 , wherein the antibody comprises a heavy chain consisting of the amino acid sequence ranging from amino acid residue 20 to amino acid residue 466 of SEQ ID NO: 7 and a light chain consisting of the amino acid sequence ranging from amino acid residue 23 to amino acid residue 236 of SEQ ID NO: 8. This application is a continuation of U.S. patent application Ser. No. 14/798,302, filed Jul. 13, 2015, now U.S. Pat. No. 9,314,538, which is a continuation of U.S. patent application Ser. No. 13/830,899, filed Mar. 14, 2013, now U.S. Pat. No. 9,078,931, which is a continuation of Ser. No. 13/249,111, filed Sep. 29, 2011, now U.S. Pat. No. 8,637,642, which claims the benefit of priority from U.S. Provisional Patent Application No. 61/387,933, filed Sep. 29, 2010. The contents of each application listed in this paragraph are fully incorporated by reference herein.The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing (file name: 511582008206SeqList.txt, date recorded: Mar. 9, 2016, size: 42,033 bytes).Not applicable.The invention described herein relates to antibodies, binding fragments, and antibody drug ...

SECURE MOBILE DEVICE TWO-FACTOR AUTHENTICATION

A user of a computer seeking to access a protected resource must first authenticate with an authentication appliance. The user provides credentials to the authentication appliance for verification and for use in determining a mobile device associated with the user. The authentication appliance then dynamically generates a reference shared secret, such as an image, pattern, or key, which is also displayed to the user on the computer. The authentication appliance sends an authentication request to an application on the mobile device associated with the user. The application provides an interface in which the user may select, enter, draw, or reproduce the earlier-viewed shared secret on the mobile device. The user-provided secret is then compared to the reference shared secret. If the user-provided secret matches the reference shared secret, then the authentication appliance may provide the user or the computer access to the protected resource. 1. A computing appliance for performing multi-factor authentication , the appliance comprising:one or more processors;a computer-readable memory; and obtain a set of user credentials from a client computer, wherein the set of user credentials are associated with a user identity;', 'access a database containing a set of reference user credentials;', 'verify the user identity by comparing the set of user credentials with the set of reference user credentials;', 'determine a mobile device associated with the user identity;', 'generate a shared secret;', 'transmit the shared secret to the client computer to be displayed on the client computer;', 'transmit an authentication request to the mobile device, wherein the authentication request is configured to be accessed by an application on the mobile device in order to obtain a user-supplied secret;', 'obtain an authentication response from the mobile device;', 'upon obtaining the authentication response, verify the user-supplied secret matches the shared secret; and', 'upon verifying ...

ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS

Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer. 1. An antibody drug conjugate comprising an antibody or antigen binding fragment conjugated to monomethyl auristatin E (MMAE), wherein the antibody or fragment comprises the heavy chain variable region consisting of the amino acid sequence ranging from 20E to the 136S of SEQ ID NO:7 and the light chain variable region consisting of the amino acid sequence ranging from 23D to the 130R SEQ ID NO:8. This application is a continuation of U.S. patent application Ser. No. 13/830,899, filed Mar. 14, 2013, now U.S. Pat. No. 9,078,931, which is a continuation of Ser. No. 13/249,111, filed Sep. 29, 2011, now U.S. Pat. No. 8,637,642, which claims the benefit of priority from U.S. Provisional Patent Application No. 61/387,933, filed Sep. 29, 2010. The contents of each application listed in this paragraph are fully incorporated by reference herein.The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing (file name: 511582008205SeqList.txt, date recorded: Jul. 7, 2015, size: 41,999 bytes).Not applicable.The invention described herein relates to antibodies, binding fragments, and antibody drug conjugates (ADCs) thereof, that bind proteins, termed 191P4D12. The invention further relates to prognostic, prophylactic and therapeutic methods and compositions useful in the treatment of cancers that express 191P4D12.Cancer is the second leading cause of human death next to coronary disease. Worldwide, millions of people die from cancer every year. In the United States alone, as reported by the American Cancer Society, cancer causes the death of ...

ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS

Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer. 1. (canceled)2. An antibody drug conjugate comprising an anti-191P4D12 antibody or antigen binding fragment thereof , wherein the antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising complementarity determining regions (CDRs) comprising the amino acid sequences of the CDRs in the heavy chain variable region sequence set forth in SEQ ID NO: 7 and a light chain variable region comprising CDRs comprising the amino acid sequences of the CDRs in the light chain variable region sequence set forth in SEQ ID NO: 8 , and wherein the antibody or antigen binding fragment thereof is conjugated to one or more units of monomethyl auristatin E (MMAE) , each unit being conjugated via a linker.3. The antibody drug conjugate of claim 2 , wherein the antibody or fragment comprises the heavy chain variable region comprising an amino acid residue 20 to amino acid residue 136 of SEQ ID NO:7 and the light chain variable region comprising an amino acid residue 23 to amino acid residue 130 of SEQ ID NO:8.4. The antibody drug conjugate of claim 2 , wherein the antibody comprises a heavy chain comprising an amino acid residue 20 to amino acid residue 466 of SEQ ID NO:7 and a light chain comprising the amino acid residue 23 to amino acid residue 236 of SEQ ID NO:8.5. The antibody drug conjugate of claim 2 , wherein the antigen binding fragment is an Fab claim 2 , F(ab′) claim 2 , Fv or scFv fragment.6. The antibody drug conjugate of claim 2 , wherein the antibody is a fully human antibody.7. The antibody drug conjugate of claim 2 , wherein the antibody or antigen binding fragment is recombinantly produced.9. The ...

STRING TRIMMER HEAD

A trimmer head, a line holder and a method. The head may include a housing rotatable about an axis; a line holder supported by the housing, the line holder defining a first receptacle, a second receptacle separated from the first receptacle and an opening communicating with the first receptacle and the second receptacle; and a line supportable by the line holder, the line having a first end and an opposite second end, the line being folded to provide a first line section from the first end toward a folded portion and a second line section from the second end toward the folded portion, the folded portion being insertable into the opening, the first line section being received in the first receptacle, the second line section being received in the second receptacle. 1. A trimmer head for use with a trimmer , the head comprising:a housing rotatable about an axis; anda line holder supported by the housing, the line holder defining a first receptacle, a second receptacle separated from the first receptacle and an opening communicating with the first receptacle and the second receptacle, the line holder being operable to support a line, the line having a first end and an opposite second end, the line being folded to provide a first line section from the first end toward a folded portion and a second line section from the second end toward the folded portion, the folded portion being insertable into the opening, the first line section being receivable in the first receptacle, the second line section being receivable in the second receptacle.2. The head of claim 1 , wherein the line holder includes a projection separating the first receptacle from the second receptacle.3. The head of claim 2 , wherein the folded portion is positionable around the projection to retain the line in the line holder.4. The head of claim 2 , wherein the projection has a first side and a second side extending to a free end claim 2 , the first side defining a portion of the first receptacle and a ...

ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS

Antibody drug conjugates (ADC's) that bind to 161P2F10B protein are described herein. 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.

ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS

Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer. 1. An antibody drug conjugate comprising an antibody or antigen binding fragment to monomethyl auristatin E (MMAE), wherein the antibody or fragment comprises the heavy chain variable region consisting of the amino acid sequence ranging from 1Q to the 120S of SEQ ID NO: 7 and the light chain variable consisting of the amino acid sequence ranging from 1D to the 113R SEQ ID NO: 8. This application is a continuation of U.S. application Ser. No. 14/634,606, filed 27 Feb. 2015, now pending, which is a continuation of U.S. application Ser. No. 13/975,214, filed 23 Aug. 2013, now U.S. Pat. No. 8,968,742, which claims priority to U.S. Provisional Patent Application No. 61/692,448, filed 23 Aug. 2012. All applications are herein incorporated by reference in their entirety for all purposes.The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing (file name: 511582505002SeqList.txt, date recorded: Mar. 25, 2016, size: 40,227 bytes.The invention described herein relates to antibodies, binding fragments, and antibody drug conjugates (ADCs) thereof, that bind proteins, termed 158P1D7. The invention further relates to prognostic, prophylactic and therapeutic methods and compositions useful in the treatment of cancers that express 158P1D7.Cancer is the second leading cause of human death next to coronary disease. Worldwide, millions of people die from cancer every year. In the United States alone, as reported by the American Cancer Society, cancer causes the death of well over a half-million people annually, ...

Novel aryllithium products and processes

An improved process for producing high purity solutions of aryllithium compounds comprising reacting a particulate alkali metal having a particle size in the range of 10 to 300 microns, with an aryl halide in a normally liquid etheral solvent of the formula ROR1, wherein R and R1 are selected from the group of alkyl radicals containing from 3 to 6 carbon atoms, in the presence of a Lewis base compound selected from compounds of the formula: R?2AR3(R4)¿z and (I), wherein A is selected from oxygen, nitrogen, phosphorus or sulfur; R?2, R3, and R4¿ are selected from alkyl radicals containing from 1 to 6 carbon atoms; R?5 and R6¿ are independently selected from hydrogen or alkyl radicals containing one to six carbon atoms; y is an integer from 4 to 6; but when A is oxygen or sulfur, z is zero; and when A is nitrogen or phosphorus, z is one, and provided there is a mole ratio of ether to aryl halide of at least 1.3 to 1 and a mole ratio of Lewis base to aryl halide of from 0.01 to 0.50; and products of the process.

Improved method of preparation of lithium alkylamides

Slurry and process for the mechano-chemical polishing of semiconductor devices

This invention is for an improved slurry for shallow trench isolation processing. The improved slurry has an enhanced oxide to nitride polish removal selectivity. The invention relates to a modified slurry formed by mixing a polishing slurry with tetramethyl ammonium hydroxide and hydrogen peroxide. In an alternative embodiment, the modified slurry is formed by mixing a salt of tetramethyl ammonium with a base and with hydrogen peroxide to form the modified slurry.

Antibodies and related molecules that bind to 24p4c12 proteins

Antibodies and molecules derived therefrom that bind to 24P4C12 protein and variants thereof, are described wherein 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 24P4C12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 24P4C12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 24P4C12 can be used in active or passive immunization.

Conjugados de anticuerpo farmaco (adc) que enlazan a las proteinas 158p1d7.

La presente invención se refiere a conjugados de anticuerpo fármaco (ADC´s) que enlazan a la proteína 158P1D7 y variantes de la misma. La proteína 158P1D7 exhibe expresión específica de tejido en el tejido de adulto normal, y se expresa aberrantemente en los cánceres listados en la Tabla I. Consecuentemente, los ADC´s de la invención proporcionan una composición terapéutica para el tratamiento de cáncer.

Doping of carbon foams for use in energy storage devices

A polymeric foam precursor, wetted with phosphoric acid, is pyrolyzed in an inert atmosphere to produce an open-cell doped carbon foam, which is utilized as a lithium intercalation anode in a secondary, organic electrolyte battery. Tests were conducted in a cell containing an organic electrolyte and using lithium metal counter and reference electrodes, with the anode located therebetween. Results after charge and discharge cycling, for a total of 6 cycles, indicated a substantial increase in the energy storage capability of the phosphorus doped carbon foam relative to the undoped carbon foam, when used as a rechargeable lithium ion battery.

Functionalized chain extended initiators for anionic polymerization

A process for the preparation of hydrocarbon solutions of monofunctional ether initiators of the following general structure: M--Q.sub.n --Z--OA(R.sup.1 R.sup.2 R.sup.3) wherein M is defined as an alkali metal, selected from the group consisting of lithium, sodium and potassium, Q is a saturated or unsaturated hydrocarbyl group derived by incorporation of a compound selected from the group consisting of conjugated diene hydrocarbons and alkenylsubstituted aromatic hydrocarbons; Z is a branched or straight chain hydrocarbon group which contains 3-25 carbon atoms, optionally containing aryl or substituted aryl groups; A is an element selected from carbon and silicon; R 1 , R 2 , and R 3 are independently selected from hydrogen, alkyl, substituted alkyl groups containing lower alkyl, lower alkylthio, and lower dialkylamino groups, aryl or substituted aryl groups containing lower alkyl, lower alkylthio, and lower dialkylamino groups, and n is an integer from 1 to 5, monofunctional ethers produced by the process, use of the initiators in a polymerization process and polymers produced by the polymerization process.

Functionalized amine initiators for anionic polymerization

A process for the preparation of hydrocarbon solutions of monofunctional amine initiators of the following general structures: ##STR1## wherein M is defined as an alkali metal, selected from the group consisting of lithium, sodium and potassium, Q is a saturated or unsaturated hydrocarbyl group derived by incorporation of a compound selected from the group consisting of conjugated diene hydrocarbons and alkenyl substituted aromatic hydrocarbons; Z is a hydrocarbon tether group which contains 3-25 carbon atoms; A is an element selected from Group IVa of the periodic table and R 1 , R 2 , and R 3 are independently selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, aryl or substituted aryl groups, m is an integer from 0 to 7, and n is an integer from 1 to 5, monofunctional amine initiators produced by the process, use of the initiators in a polymerization process and polymers produced by the polymerization process.

Funktionelle starter mit verlängerter kette für die anionische polymerisation

Organolithium polymerization initiators and use thereof in polymerization processes

Functionalized chain extended initiators for anionic polymerization

A process for the preparation of hydrocarbon solutions of monofunctional ether initiators of the following general structure: M-Qn-Z-OA(R1R2R3) wherein M is defined as an alkali metal, selected from the group consisting of lithium, sodium and potassium, Q is a saturated or unsaturated hydrocarbyl group derived by incorporation of a compound selected from the group consisting of conjugated diene hydrocarbons and alkenylsubstituted aromatic hydrocarbons; Z is a branched or straight chain hydrocarbon group which contains 3-25 carbon atoms, optionally containing aryl or substituted aryl groups; A is an element selected from carbon and silicon; R?1, R2, and R3¿ are independently selected from hydrogen, alkyl, substitued alkyl groups containing lower alkyl, lower alkylthio, and lower dialkylamino groups, aryl or substituted aryl groups containing lower alkyl, lower alkylthio, and lower dialkylamino groups, and n is an integer from 1 to 5, monofunctional ethers produced by the process, use of the initiators in a polymerization process and polymers produced by the polymerization process.

Optical tracking vehicle control system and method

A vehicle control system having a controller and a spatial database adapted to provide spatial data to the controller at control speed. The spatial data provided from the spatial database to the controller includes images collected from an optical sensor subsystem in addition to other data collected by a variety of sensor types, including a GNSS or inertial measurement system. The spatial data received by the controller from the database forms at least part of the control inputs that the controller operates on to control the vehicle. The advantage provided by the present invention allows control system to “think” directly in terms of spatial location. A vehicle control system in accordance with one particular embodiment of the invention comprises a task path generator, a spatial database, at least one external spatial data receiver, a vehicle attitude compensation module, a position error generator, a controller, and actuators to control the vehicle.

Vehicle control system

A vehicle control system having a controller and a spatial database adapted to provide spatial data to the controller at control speed. The spatial data provided from the spatial database to the controller can be any kind of data or information that has some relationship or association with “real world” geographical location, or if it is stored somehow with reference to geographical location. The spatial data received by the controller from the database forms at least part of the control inputs that the controller operates on to control the vehicle. The fact that the controller operates directly on information that is inherently associated with “real world” geographic location represents a change in thinking compared with existing vehicle control systems. In particular, it means that the control system of the present invention “thinks” directly in terms of spatial location. A vehicle control system in accordance with one particular embodiment of the invention comprises a task path generator, a spatial database, at least one external spatial data receiver, a vehicle attitude compensation module, a position error generator, a controller, and actuators to control the vehicle.

Soluble coffee composition

A coffee extract or concentrate and a soluble coffee which are similar to roast and ground coffee solubles in composition of moderately volatile flavor components are disclosed. The soluble coffee composition also contains less of the off-flavor compo­ nents normally found in high quantities in conventional instant coffees. The coffees are characterized by high pyrazines deriva­ tive content and low content of furfural. This soluble coffee composition can be aromatized for use as a premium soluble coffee product. Alternatively, it is compatible for mixing with conventional roast and ground coffee in single- and multiple-­ serving brewing articles, such as coffee bags.

Methods and personal protection devices for repelling insects

Methods and devices for repelling insects are disclosed. The methods and devices provide personal protection from insect bites and insect landings, particularly mosquito bites. The methods and devices employ insect repellents such as pyrethroids at low (parts per billion) levels. The methods and devices effectively minimize the number of mosquitoes landing on a subject properly using the devices.

Antibody drug conjugates (adc) that bind to 161p2f10b proteins

Antibody drug conjugates (ADC's) that bind to 161P2F10B protein are described herein. 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.

Antibody drug conjugates (adc) that bind to 191p4d12 proteins

Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.

Antibody drug conjugates (adc) that bind to 158p1d7 proteins

The invention provides an antibody-drug conjugate comprising an anti-158P1D7 antibody or antigen binding fragment thereof conjugated to monomethyl auristatin E (MMAE), wherein the antibody or fragment thereof comprises a heavy chain variable region comprising an amino acid sequence at least 80% homologous to the heavy chain variable region amino acid sequence set forth in SEQ ID NO:7 and a light chain variable region comprising an amino acid sequence at least 80% homologous to the light chain variable region amino acid sequence set forth in SEQ ID NO:8.

Antibody drug conjugates (adc) that bind to 161p2f10b proteins

The present invention provides antibody drug conjugates or antigen binding fragment thereof that bind to 161P2F10B protein, wherein the antibody or antigen binding fragment thereof is conjugated to one or more units of monomethyl auristatin F (MMAF), each unit being conjugated via a linker. Provided are also antibody drug conjugates for use as a medicament, and pharmaceutical compositions that comprise the antibody drug conjugates in a human unit dose form. Further provided are antibody drug conjugates or the pharmaceutical compositions of the invention for use in treating cancer/tumor or inhibiting cancer/tumor growth in a subject.

Antibody drug conjugates (adc) that bind to 191p4d12 proteins

The present disclosure relates to antibody drug conjugates (ADC's) with auristatin E that binds to 191P4D12 protein and variants thereof. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in some cancers. The ADC's of provide a therapeutic composition for the treatment of cancer.

Antibody drug conjugates (adc) that bind to 191p4d12 proteins

The present invention provides nucleotides encoding an anti-191P4D12 antibody or antigen binding fragment thereof, vectors comprising the nucleotides, and cells comprising the vectors. The invention further provides methods of producing the antibodies of the invention and its fragments as well as antibody-drug conjugates using the cells of the invention.

Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers

Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers

A polynucleotide that encodes 158P1D7 protein, wherein the polynucleotide is: (a) a polynucleotide comprising the sequence of SEQ ID NO:8, from nucleotide residue number 23 through 1210; or (b) a polynucleotide comprising the sequence of SEQ ID NO:10, from nucleotide residue number 23 through 1612 encodes a protein that can be used to immunise an animal or raise antibodies. Cells expressing the protein can be detected, or growth and/or survival of a cell expressing the protein inhibited.

Antibodies and related molecules that bind to psca proteins

Antibody drug conjugates (adc) that bind to 158p1d7 proteins

Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.

Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers

The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.

Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers

The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.

Antibody drug conjugates (adc) that bind to 158p1d7 proteins

Antibody drug conjugates (ADC) that bind to 158P1D7 proteins

Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.

Antibody drug conjugates (ADC) that bind to 158P1D7 proteins

Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.

Antibody drug conjugates (ADC) that bind to 158P1D7 proteins

Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.

Antibody drug conjugates (ADC) that bind to 158P1D7 proteins

Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.

Antibody drug conjugates (ADC) that bind to 158P1D7 proteins

Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.

Antibody drug conjugates (adc) that bind to 158p1d7 proteins

Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers

A novel gene (designated 158P1D7) and its encoded protein are described. While 158P1D7 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including set forth in Table 1. Consequently, 158P1D7 provides a diagnostic and/or therapeutic target for cancers. The 158P1D7 gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit an immune response.

Ether free organometallic amide compositions

Preparation of organometallic and organobimetallic compounds

A method for producing methyllithium solutions by reacting a methylhalide with a mixture of lithium metal and an aromatic hydrocarbon containing tetrahydrofuran.

Toothbrush with severable electrical connections

Disclosed is an electrical connector having particular application in an oral care implement having a removable and/or replaceable head. In particular, an electric toothbrush having a removable brush head and/or head and neck assembly and a severable electrical connector is disclosed in which the brush head includes one or more elements requiring a source of electrical power. The severable electrical connector provides electrical communication between the brush head and a power source retained within the handle or handle portion of the toothbrush.

Methods to inhibit growth of prostate cancer cells

A novel gene (designated 101P3A11 or PHOR-1) and its encoded protein, and variants thereof, are described wherein 101P3A11 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 101P3A11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 101P3A11 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 101P3A11 can be used in active or passive immunization.

Convection oven

A convection oven having an insulated oven chamber bounded by a front access door, a floor, a ceiling, two side walls, and a rear wall. An inlet air passageway, which includes a heating element, delivers heated air to the oven chamber, and an exhaust passageway exhausts air from the oven chamber. A baffle plate spaced from the rear wall divides the oven chamber into a blower compartment and a baking compartment, which are connected by a return air opening in the baffle plate and at least one peripheral opening outwards of the return air opening. A blower fan in the blower compartment draws heated air into the oven chamber, mixes the heated air with air already inside the even chamber, circulates the mixed air throughout the oven chamber, and expels air through the exhaust passageway. To alleviate problems caused by high and low pressure zones created in diagonally opposing corners of the blower compartment by rotation of the blower fan, two pairs of diverter plates are disposed around the blower fan. These diverter plates are configured so as to reduce the air pressure in the otherwise high pressure corners and to increase the air pressure in the otherwise low pressure corners. Additionally, the diverter plates create negative pressure to draw air from the combustion chamber into the oven chamber. Each pair of diverter plates is disposed along separate diametrical axes that are perpendicular to each other. In addition, one pair of diverter plates is disposed closer to the blower fan than the other. The diverter plates cooperate with one another in such as way as to mimic air pumps that divert air away from the high-pressure corners and into the low-pressure corners. Thus, the diverter plates tend to equalize the air pressure among the corners of the blower compartment. This helps equalize the air pressure throughout the oven chamber, which in turn ensures even cooking of food.

Method of preparation of lithium alkylamides

A process for quickly preparing easily separable solutions of lithium alkylamides, as exemplified by the formula (R.sub.3 M).sub.x NLi(R1).sub.y.(LB).sub.z (I) wherein M is silicon or carbon, R and R 1 are C 1 -C 8 alkyl, cycloalkyl or alkylene groups, LB is a Lewis base, x and y are integers equaling 2, and z is greater than 1, comprising the steps of reacting lithium metal in bulk form with an alkylamine in mole ratios of metal to alkylamine ranging from 2 to 1 to 10 to 1 in a solvent selected from ethereal or selected from the group consisting of conjugated dienes, vinyl aromatic and polycyclic aromatic compounds, under an inert atmosphere at elevated temperatures for 1 to 10 hours, cooling the product and separating the product solution from the unreacted lithium metal in the reactor.

Ultrasonic spray apparatus to coat a substrate

Fluid is ejected from a surface of an apparatus. The apparatus comprises a.) a power supply operating at a frequency; b.) a transducer, which upon being applied the power is made to vibrate with a first amplitude; c.) a vibrating nozzle, comprising the surface, which is acoustically coupled to the transducer, to transmit the transducer vibration to the surface with a second amplitude; and, d.) a control unit to control the power supply applied to the transducer. The fluid is delivered to the surface of the nozzle. During this time the control unit cycles the power applied to the transducer at the frequency between a low power level and a high power level. The fluid is ejected from the surface when the high power level (i.e., first power level) is applied to the transducer but not when the low power level (i.e., second power level) is applied to the transducer.

Pipe connector

Catalyzed hydrocarbyllithium process

A catalytic process for alkylating an alkali metal selected from lithium, sodium and potassium with an alkyl halide containing 3 to 20 carbon atoms comprising conducting the reaction in a hydrocarbon solvent in the presence of a catalytic compound represented by the formula (RR1R2Ma)yA(R3)x wherein R, R1 and R2 are independently selected from hydrogen, halogen, alkyl, alkenyl, cycloalkyl, and aryl groups, R3 is independently selected from aryl groups containing 6 to 18 carbon atoms, four to six-membered heterocyclic carbon containing groups containing one to two hetero atoms selected from oxygen, nitrogen, and sulfur; hydroxyalkyl, alkoxyalkyl and monoalkylamino-alkyl and dialkylaminoalkyl groups containing 2 to 13 carbon atoms; Ma is selected from silicon, carbon, germanium, and tin, A is selected from oxygen, sulfur, nitrogen and phosphorus, and x and y independently have values from zero to three.

Nucleic acid and corresponding protein entitled 151p3d4 useful in treatment and detection of cancer

A novel gene (designated 151P3D4) and its encoded protein, and variants thereof, are described wherein 151P3D4 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table 1. Consequently, 151P3D4 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 151P3D4 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 151P3D4 can be used in active or passive immunization.

Antibody drug conjugates (adc) that bind to 158p1d7 proteins 158p1d7 (adc)

Catalyzed hydrocarbyllithium process

A catalytic process for alkylating an alkali metal selected from lithium, sodium and potassium with an alkyl halide containing 3 to 20 carbon atoms comprising conducting the reaction in the presence of a catalytic compound represented by the formula (RR.sup.1 R.sup.2 M.sup.a)yA(R.sup.3)x wherein R, R 1 and R 2 are independently selected from hydrogen, halogen, alkyl, alkenyl, cycloalkyl, and aryl groups, R 3 is independently selected from aryl groups containing 6 to 18 carbon atoms, four to six-membered heterocyclic carbon containing groups containing one to two hetero atoms selected from oxygen, nitrogen, and sulfur; hydroxyalkyl, alkoxyalkyl and monoalkylaminoalkyl and dialkylaminoalkyl groups containing 2 to 13 carbon atoms; M a is selected from silicon, carbon, germanium, and tin, A is selected from oxygen, sulfur, nitrogen and phosphorus, and x and y independently have values from zero to three.

Nucleic acid and corresponding protein entitled 162p1e6 useful in treatment and detection of cancer

A novel gene (designated 162P1E6) and its encoded protein, and variants thereof, are described wherein 162P1E6 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 162P1E6 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 162P1E6 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 162P1E6 can be used in active or passive immunization.

Antibody drug conjugates (adc) that bind to 161p2f10b proteins

Antibody drug conjugates (ADC's) that bind to 161P2F10B protein are described herein. 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.

Nucleic acid and corresponding protein entitled 184p1e2 useful in treatment and detection of cancer

A novel gene (designated 184P1E2) and its encoded protein, and variants thereof, are described wherein 184P1E2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 184P1E2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 184P1E2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 184P1E2 can be used in active or passive immunization.

Endless belt and drum type vacuum filter

Toothbrush with severable electrical connections

Disclosed is an electrical connector having particular application in an oral care implement having a removable and/or replaceable head. In particular, an electric toothbrush having a removable brush head and/or head and neck assembly and a severable electrical connector is disclosed in which the brush head includes one or more elements requiring a source of electrical power. The severable electrical connector provides electrical communication between the brush head and a power source retained within the handle or handle portion of the toothbrush.